<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="pmc-domain-id">2103</journal-id><journal-id journal-id-type="pmc-domain">pharmamdpi</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9788085</article-id><article-id pub-id-type="pmcid-ver">PMC9788085.1</article-id><article-id pub-id-type="pmcaid">9788085</article-id><article-id pub-id-type="pmcaiid">9788085</article-id><article-id pub-id-type="pmid">36559246</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics14122752</article-id><article-id pub-id-type="publisher-id">pharmaceutics-14-02752</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Locoregional Lymphatic Delivery Systems Using Nanoparticles and Hydrogels for Anticancer Immunotherapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Cho</surname><given-names initials="KJ">Kyeong Jin</given-names></name><xref rid="af1-pharmaceutics-14-02752" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9864-0265</contrib-id><name name-style="western"><surname>Cho</surname><given-names initials="YE">Young-Eun</given-names></name><xref rid="af2-pharmaceutics-14-02752" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7091-8050</contrib-id><name name-style="western"><surname>Kim</surname><given-names initials="J">Jihoon</given-names></name><xref rid="af1-pharmaceutics-14-02752" ref-type="aff">1</xref><xref rid="c1-pharmaceutics-14-02752" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Shi</surname><given-names initials="X">Xiangyang</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Rafael</surname><given-names initials="D">Diana</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-14-02752"><label>1</label>Division of Biological Science and Technology, Yonsei University, Wonju 26493, Republic of Korea</aff><aff id="af2-pharmaceutics-14-02752"><label>2</label>Department of Food and Nutrition, Andong National University, Andong 36729, Republic of Korea</aff><author-notes><corresp id="c1-pharmaceutics-14-02752"><label>*</label>Correspondence: <email>jihoonkim@yonsei.ac.kr</email></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>12</month><year>2022</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2022</year></pub-date><volume>14</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">423613</issue-id><elocation-id>2752</elocation-id><history><date date-type="received"><day>28</day><month>10</month><year>2022</year></date><date date-type="accepted"><day>07</day><month>12</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>12</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>24</day><month>12</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-08 21:25:36.357"><day>08</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2022 by the authors.</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceutics-14-02752.pdf"/><abstract><p>The lymphatic system has gained significant interest as a target tissue to control cancer progress, which highlights its central role in adaptive immune response. Numerous mechanistic studies have revealed the benefits of nano-sized materials in the transport of various cargos to lymph nodes, overcoming barriers associated with lymphatic physiology. The potential of sustained drug delivery systems in improving the therapeutic index of various immune modulating agents is also being actively discussed. Herein, we aim to discuss design rationales and principles of locoregional lymphatic drug delivery systems for invigorating adaptive immune response for efficient antitumor immunotherapy and provide examples of various advanced nanoparticle- and hydrogel-based formulations.</p></abstract><kwd-group><kwd>cancer immunotherapy</kwd><kwd>lymph nodes</kwd><kwd>drug delivery</kwd><kwd>nanoparticles</kwd><kwd>hydrogels</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-14-02752"><title>1. Introduction</title><p>Immunotherapy has garnered attention in anticancer therapy owing to advances in biotechnology and expanded understanding of the complex immune networks in cancer progression [<xref rid="B1-pharmaceutics-14-02752" ref-type="bibr">1</xref>]. Cancer cells create immunosuppressive &#8220;cold&#8221; tumor microenvironments to evade the body&#8217;s immune surveillance [<xref rid="B2-pharmaceutics-14-02752" ref-type="bibr">2</xref>]. Immune checkpoint blockades (ICBs), such as antagonistic cytotoxic T-lymphocyte-associated protein (CTLA)-4, anti-programmed cell death (PD)-1, and anti-PD-ligand (PD-L)-1 monoclonal antibodies (mAbs), which are clinically approved by the U.S. Food and Drug Administration (FDA), are representative immunotherapeutics that reprogram these &#8220;cold&#8221; tumors to &#8220;hot&#8221; tumors that are not only characterized by abundant cytotoxic CD8<sup>+</sup> T cells (CTLs) and natural killer (NK) cells, but are also responsive to these immune cells [<xref rid="B2-pharmaceutics-14-02752" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-14-02752" ref-type="bibr">3</xref>]. The therapeutic effects of chemotherapy, the most widely utilized anticancer methodology in the clinic, are found to be either mainly or partially dependent on direct or indirect immuno-modulatory effects of the drugs. As a result, recent re-evaluation and re-purposing of the traditional chemotherapeutics in terms of chemoimmunotherapy have accelerated [<xref rid="B4-pharmaceutics-14-02752" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceutics-14-02752" ref-type="bibr">5</xref>]. Accordingly, the anticancer therapy paradigm has been shifting from being heavily focused on cancer cells to a comprehensive consideration of localized tumor microenvironment and systemic immune responses [<xref rid="B1-pharmaceutics-14-02752" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceutics-14-02752" ref-type="bibr">2</xref>,<xref rid="B4-pharmaceutics-14-02752" ref-type="bibr">4</xref>]. </p><p>Current anticancer immunotherapy can be roughly categorized into two strategies: Initiation of anticancer immunity by improving the susceptibility of cancer cells to immune cells to exert anticancer effects in tumor microenvironments. This strategy includes the induction of immunogenic cell death (ICD) to release adenosine triphosphate (ATP), calreticulin (CRT), and high mobility group box protein 1 (HMGB-1) for the recruitment of dendritic cells (DCs) that phagocytize cancer cells or their antigens [<xref rid="B4-pharmaceutics-14-02752" ref-type="bibr">4</xref>,<xref rid="B6-pharmaceutics-14-02752" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-14-02752" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-14-02752" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-14-02752" ref-type="bibr">9</xref>], suppression of immunosuppressive pathways of cancer cells [<xref rid="B10-pharmaceutics-14-02752" ref-type="bibr">10</xref>] or cancer-associated ECM-resident cells [<xref rid="B11-pharmaceutics-14-02752" ref-type="bibr">11</xref>], or inhibition of the signals associated with the immune checkpoints between cancer cells and immune cells [<xref rid="B3-pharmaceutics-14-02752" ref-type="bibr">3</xref>,<xref rid="B7-pharmaceutics-14-02752" ref-type="bibr">7</xref>,<xref rid="B12-pharmaceutics-14-02752" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-14-02752" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-14-02752" ref-type="bibr">14</xref>]. Accordingly, nano-sized materials that can efficiently deliver drugs to tumor tissues via enhanced permeation and retention (EPR) serve as one of the attractive tools to achieve efficient anticancer immunotherapy [<xref rid="B4-pharmaceutics-14-02752" ref-type="bibr">4</xref>,<xref rid="B15-pharmaceutics-14-02752" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-14-02752" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-14-02752" ref-type="bibr">17</xref>]. </p><p>The lymph nodes (LNs)-centered anticancer immunotherapy to achieve efficient expansion of immune cells in the secondary lymphoid tissues, followed by increased infiltration in tumor microenvironments serves as the second strategy [<xref rid="B1-pharmaceutics-14-02752" ref-type="bibr">1</xref>,<xref rid="B5-pharmaceutics-14-02752" ref-type="bibr">5</xref>,<xref rid="B18-pharmaceutics-14-02752" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-14-02752" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceutics-14-02752" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceutics-14-02752" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceutics-14-02752" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceutics-14-02752" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceutics-14-02752" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-14-02752" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-14-02752" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-14-02752" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-14-02752" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-14-02752" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-14-02752" ref-type="bibr">30</xref>]. LNs are the primary tissues for adaptive immunity. In fact, LNs instruct and expand antigen-specific CTLs via antigen-presenting cells (APCs), such as DCs [<xref rid="B1-pharmaceutics-14-02752" ref-type="bibr">1</xref>,<xref rid="B18-pharmaceutics-14-02752" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-14-02752" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceutics-14-02752" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceutics-14-02752" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceutics-14-02752" ref-type="bibr">22</xref>]. The importance of LNs in adaptive anticancer immunotherapy has been emphasized recently. Francis et al. reported that intradermal (i.d.) injections of ICBs to the tissue ipsilateral (i.l.) to the tumor allows their preferential accumulation in draining LNs (dLNs) over tumor tissues, leading to similar therapeutic effects to intratumoral (i.t.) administration enabling tumor and tumor dLN (TdLN) accumulation [<xref rid="B31-pharmaceutics-14-02752" ref-type="bibr">31</xref>]. Similarly, Manspeaker et al. demonstrated that locoregional i.l. administration for TdLNs targeting led to a higher anticancer therapeutic index than intravenous (i.v.) administration, mainly targeting the tumor microenvironment in the combination therapy with the PD-1 monoclonal antibody (aPD-1 mAb) and nanoparticles (NPs) loaded with paclitaxel (PTX) [<xref rid="B5-pharmaceutics-14-02752" ref-type="bibr">5</xref>]. Even in the aforementioned immunotherapy strategy that primarily targets the tumor microenvironments, DCs migrated from peripheral tissues to the LNs after the uptake of antigens produced via natural apoptosis or by cytotoxic drugs, initiate and propagate the anticancer immunotherapy.</p><p>The pharmacokinetics of immuno-modulatory drugs govern therapeutic effects, side effects, and patient compliance regarding cancer immunotherapy [<xref rid="B16-pharmaceutics-14-02752" ref-type="bibr">16</xref>,<xref rid="B32-pharmaceutics-14-02752" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-14-02752" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceutics-14-02752" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceutics-14-02752" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceutics-14-02752" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceutics-14-02752" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-14-02752" ref-type="bibr">38</xref>]. A hydrogel (HG) is a 3D polymeric network that contains water and serves as one of the important classes of drug delivery systems for the sustained release of drugs. Indeed, i.t. administration of HGs has been reported to lead to prolonged accumulation of immuno-stimulatory drugs to the tumor microenvironment, leading to a higher anticancer therapeutic index than that obtained with bolus delivery [<xref rid="B32-pharmaceutics-14-02752" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-14-02752" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceutics-14-02752" ref-type="bibr">34</xref>]. In addition, locoregional i.l. administration of ICBs-loaded HGs resulted in prolonged and higher accumulations of mAbs in TdLNs, followed by improved anticancer immunotherapy [<xref rid="B31-pharmaceutics-14-02752" ref-type="bibr">31</xref>,<xref rid="B35-pharmaceutics-14-02752" ref-type="bibr">35</xref>].</p><p>After considering numerous reviews that enabled an extensive and intensive discussion of the design rationales and examples of biomaterials for the delivery of immuno-therapeutics to the tumor microenvironment [<xref rid="B1-pharmaceutics-14-02752" ref-type="bibr">1</xref>,<xref rid="B4-pharmaceutics-14-02752" ref-type="bibr">4</xref>,<xref rid="B16-pharmaceutics-14-02752" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-14-02752" ref-type="bibr">17</xref>,<xref rid="B36-pharmaceutics-14-02752" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceutics-14-02752" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-14-02752" ref-type="bibr">38</xref>], we aimed to discuss the principles, design rationales, and recent progress of lymphatic drug delivery systems to achieve efficient adaptive anticancer immunotherapy. First, the design rationales and examples of advanced NPs required to overcome physiological barriers of lymphatic systems were summarized in conjunction with detailed immune response. Second, several advanced HGs that enable prolonged adaptive immune response in LNs were discussed. Finally, hybrid HGs and NPs systems that allow sustained delivery of drug-loaded NPs to the LNs for efficient anticancer immunotherapy were introduced. </p></sec><sec id="sec2-pharmaceutics-14-02752"><title>2. Advanced NPs for LNs Targeting and Adaptive Cancer Immunotherapy</title><sec id="sec2dot1-pharmaceutics-14-02752"><title>2.1. Basic Criteria for the Lymphatic Delivery of NPs and Immunomodulatory Drugs</title><p>LNs-centered adaptive cancer immunotherapy requires a cascade pathway. First, NPs containing immuno-modulatory drugs should drain into the LNs [<xref rid="B18-pharmaceutics-14-02752" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-14-02752" ref-type="bibr">19</xref>,<xref rid="B21-pharmaceutics-14-02752" ref-type="bibr">21</xref>]. In locoregional administration of NPs, such as i.d., i.t., subcutaneous (s.c), or intramuscular (i.m.), the transport of NPs to dLNs depends on interstitial flow, a bulk fluid flow for transit to the initial lymphatics within tissues [<xref rid="B18-pharmaceutics-14-02752" ref-type="bibr">18</xref>,<xref rid="B39-pharmaceutics-14-02752" ref-type="bibr">39</xref>]. NPs with a hydrodynamic size ranging from 10 to 50 nm can efficiently pass through the pores of the extracellular matrix of tissues in bulk [<xref rid="B40-pharmaceutics-14-02752" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceutics-14-02752" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-14-02752" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-14-02752" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-14-02752" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-14-02752" ref-type="bibr">45</xref>]. However, the size threshold for delivery into the lymphatics can differ based on the flexibility and rigidity of the nanomaterials [<xref rid="B40-pharmaceutics-14-02752" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceutics-14-02752" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-14-02752" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-14-02752" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-14-02752" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-14-02752" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-14-02752" ref-type="bibr">46</xref>]. Further, NPs with negative surface charges display a higher transport to the lymphatics than NPs with positive charges, which is due to the negative charge of the ECM [<xref rid="B43-pharmaceutics-14-02752" ref-type="bibr">43</xref>,<xref rid="B47-pharmaceutics-14-02752" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceutics-14-02752" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceutics-14-02752" ref-type="bibr">49</xref>,<xref rid="B50-pharmaceutics-14-02752" ref-type="bibr">50</xref>]. In this regard, the surface modification of polyethylene glycol (PEG) to facilitate anti-biofouling [<xref rid="B51-pharmaceutics-14-02752" ref-type="bibr">51</xref>] and neutralization of surface charges can improve the lymphatic delivery efficacy of NPs [<xref rid="B52-pharmaceutics-14-02752" ref-type="bibr">52</xref>,<xref rid="B53-pharmaceutics-14-02752" ref-type="bibr">53</xref>,<xref rid="B54-pharmaceutics-14-02752" ref-type="bibr">54</xref>,<xref rid="B55-pharmaceutics-14-02752" ref-type="bibr">55</xref>]. In particular, lymph-homing and migratory APCs contribute to the cell-mediated lymphatic delivery of NPs not only via phagocytosis [<xref rid="B27-pharmaceutics-14-02752" ref-type="bibr">27</xref>,<xref rid="B41-pharmaceutics-14-02752" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-14-02752" ref-type="bibr">42</xref>,<xref rid="B44-pharmaceutics-14-02752" ref-type="bibr">44</xref>,<xref rid="B52-pharmaceutics-14-02752" ref-type="bibr">52</xref>], but also selective interaction with NPs engineered for modification with mannose, mannan, hyaluronic acid, hyaluronan, and antibodies to bind to the receptors of APCs [<xref rid="B56-pharmaceutics-14-02752" ref-type="bibr">56</xref>,<xref rid="B57-pharmaceutics-14-02752" ref-type="bibr">57</xref>,<xref rid="B58-pharmaceutics-14-02752" ref-type="bibr">58</xref>,<xref rid="B59-pharmaceutics-14-02752" ref-type="bibr">59</xref>,<xref rid="B60-pharmaceutics-14-02752" ref-type="bibr">60</xref>,<xref rid="B61-pharmaceutics-14-02752" ref-type="bibr">61</xref>,<xref rid="B62-pharmaceutics-14-02752" ref-type="bibr">62</xref>,<xref rid="B63-pharmaceutics-14-02752" ref-type="bibr">63</xref>,<xref rid="B64-pharmaceutics-14-02752" ref-type="bibr">64</xref>]. During systemic delivery of NPs, such as intravenous (i.v.) or intraperitoneal (i.p.), NPs in the bloodstream can access LNs via high endothelial venules (HEVs) enabling transmigration of lymphocytes interacting with peripheral node addressin (PANd) in LNs [<xref rid="B18-pharmaceutics-14-02752" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-14-02752" ref-type="bibr">19</xref>,<xref rid="B65-pharmaceutics-14-02752" ref-type="bibr">65</xref>,<xref rid="B66-pharmaceutics-14-02752" ref-type="bibr">66</xref>,<xref rid="B67-pharmaceutics-14-02752" ref-type="bibr">67</xref>,<xref rid="B68-pharmaceutics-14-02752" ref-type="bibr">68</xref>,<xref rid="B69-pharmaceutics-14-02752" ref-type="bibr">69</xref>], which can be improved when NPs are decorated with PNAd-targeting antibodies [<xref rid="B70-pharmaceutics-14-02752" ref-type="bibr">70</xref>,<xref rid="B71-pharmaceutics-14-02752" ref-type="bibr">71</xref>,<xref rid="B72-pharmaceutics-14-02752" ref-type="bibr">72</xref>]. Second, immuno-modulatory drugs that reach the afferent lymphatic vessels of LNs can access the LN parenchyma when NPs or drugs released from NPs are smaller than 70 kDa in size [<xref rid="B73-pharmaceutics-14-02752" ref-type="bibr">73</xref>]. APCs that have already encountered NPs and immuno-modulatory drugs, or other migratory immune cells interacting with NPs containing immuno-modulatory drugs, facilitate cell-mediated delivery to the cortex and paracortex regions of LNs, where adaptive immune responses occur [<xref rid="B74-pharmaceutics-14-02752" ref-type="bibr">74</xref>,<xref rid="B75-pharmaceutics-14-02752" ref-type="bibr">75</xref>,<xref rid="B76-pharmaceutics-14-02752" ref-type="bibr">76</xref>,<xref rid="B77-pharmaceutics-14-02752" ref-type="bibr">77</xref>,<xref rid="B78-pharmaceutics-14-02752" ref-type="bibr">78</xref>].</p></sec><sec id="sec2dot2-pharmaceutics-14-02752"><title>2.2. Advanced NPs to Exploit Passive Transport to the LNs</title><p>Passive transport involves the delivery of cargos to LNs by exploiting interstitial flow toward LNs within the ECM. Considering the physicochemical properties that enable transport through the ECM from peripheral tissues to LNs [<xref rid="B18-pharmaceutics-14-02752" ref-type="bibr">18</xref>,<xref rid="B39-pharmaceutics-14-02752" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceutics-14-02752" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceutics-14-02752" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-14-02752" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-14-02752" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-14-02752" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-14-02752" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-14-02752" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceutics-14-02752" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceutics-14-02752" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceutics-14-02752" ref-type="bibr">49</xref>,<xref rid="B50-pharmaceutics-14-02752" ref-type="bibr">50</xref>,<xref rid="B51-pharmaceutics-14-02752" ref-type="bibr">51</xref>], efficient lymphatic delivery of small molecular immuno-modulatory drugs requires advanced drug delivery systems not only to tune the physicochemical properties of cargos comprising drugs and drug delivery systems, but also to allow the loading and release of drugs at LNs. Depending on the intrinsic properties of immuno-modulatory drugs, various strategies can be employed for drug loading, such as hydrophobic/hydrophilic interactions, electrostatic interactions, nucleotides hybridization, protein engineering, or chemical conjugation. Recent advancements in NP design for efficient lymphatic passive transport are discussed below.</p><sec id="sec2dot2dot1-pharmaceutics-14-02752"><title>2.2.1. Physical Load; Hydrophobic/Hydrophilic Interactions</title><p>Micelles are one of the representative drug delivery systems that allow the loading of hydrophobic drugs into the hydrophobic core of structures formed via the self-assembly of block-copolymers comprising hydrophilic and hydrophobic segments in an aqueous solution [<xref rid="B79-pharmaceutics-14-02752" ref-type="bibr">79</xref>]. Thomas et al. utilized a micelle physically entangled by poly(propylene sulfide) (PPS) to explore the adjuvant potential of paclitaxel (PTX) in LNs. PTX-loaded PPS micelles (~30 nm) administered i.l. caused moderate suppression of B16F10 melanoma tumor growth, and were more efficient than those administered c.l. (i.d. administration to the tissue contralateral to the tumor) [<xref rid="B80-pharmaceutics-14-02752" ref-type="bibr">80</xref>]. The mechanism underlying the therapeutic effects of PTX is ascribed to the activation (CD86<sup>+</sup>, CD40<sup>+</sup> and/or MHCII<sup>+</sup>) and expansion of conventional DCs (cDCs, CD45<sup>+</sup>CD11b<sup>+</sup>CD11c<sup>+</sup>) in LNs [<xref rid="B5-pharmaceutics-14-02752" ref-type="bibr">5</xref>,<xref rid="B80-pharmaceutics-14-02752" ref-type="bibr">80</xref>,<xref rid="B81-pharmaceutics-14-02752" ref-type="bibr">81</xref>]. In particular, i.l. or i.t. administration of free aPD-1 mAbs combined with PTX-loaded PPS micelles administered i.l. significantly expanded stem-like CD8<sup>+</sup> T cells (Tcf-1<sup>+</sup>Tim-3<sup>-</sup>PD-1<sup>+</sup> CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup>) systemically in triple-negative breast cancer (TNBC) E0771 tumor models after selective accumulation in TdLNs, leading to the control of distant and local tumors [<xref rid="B5-pharmaceutics-14-02752" ref-type="bibr">5</xref>]. This series of projects suggest a strategy to re-purpose traditional drugs by exploiting micelles as lymphatic delivery systems [<xref rid="B5-pharmaceutics-14-02752" ref-type="bibr">5</xref>,<xref rid="B80-pharmaceutics-14-02752" ref-type="bibr">80</xref>,<xref rid="B81-pharmaceutics-14-02752" ref-type="bibr">81</xref>]. </p><p>Contrary to the micelles, lipid NPs and liposomes serve as a carrier for hydrophobic and hydrophilic drugs by incorporating them into the hydrophobic and hydrophilic segments of the self-assembled structures, respectively [<xref rid="B23-pharmaceutics-14-02752" ref-type="bibr">23</xref>,<xref rid="B82-pharmaceutics-14-02752" ref-type="bibr">82</xref>]. Hanson et al. utilized lipid NPs to demonstrate the potential of lymphatic accumulation of a stimulator of IFN gene (STING) agonists as a vaccine adjuvant [<xref rid="B83-pharmaceutics-14-02752" ref-type="bibr">83</xref>]. Indeed, lipid NPs (150 nm) administered s.c. led to increased accumulation of the STING agonists in dLNs and mitigated systemic exposure of the drugs in blood. Compared to soluble STING agonists, the STING agonist-loaded lipid NPs significantly improved the expansion of antigen-specific (tetramer<sup>+</sup>) CD8<sup>+</sup> T cells (CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup>) when co-administered with ovalbumin antigen (OVA), leading to a markedly higher anticancer effect in terms of survival and tumor growth [<xref rid="B83-pharmaceutics-14-02752" ref-type="bibr">83</xref>]. </p></sec><sec id="sec2dot2dot2-pharmaceutics-14-02752"><title>2.2.2. Physical Load; Electrostatic Interactions</title><p>Nucleotides and nucleic acids contain phosphate backbones that have negative charges, enabling electrostatic complexation with positive charged-materials for the development of nano-sized particles that have been explored as a non-viral gene delivery option [<xref rid="B16-pharmaceutics-14-02752" ref-type="bibr">16</xref>,<xref rid="B27-pharmaceutics-14-02752" ref-type="bibr">27</xref>]. Similarly, nucleotide adjuvants or nucleic acids encoding antigens can be efficiently formulated into NPs via electrostatic complexation for efficient lymphatic delivery. Solid lipid NPs (SLP) containing cationic phospholipids (152 nm) could not only physically load mRNA encoding OVA, tyrosinase-related protein 2 (TRP-2), or point-mutated version of glycoprotein 100 (gp100) that are melanoma self-antigens but also efficiently drain into the dLNs [<xref rid="B84-pharmaceutics-14-02752" ref-type="bibr">84</xref>], ultimately resulting in improved antigen-specific (tetramer<sup>+</sup>) CD8<sup>+</sup> T cell (CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup>) expansion and efficient tumor regression. Nucleotide-based adjuvants can be delivered to lymphoid tissues using cationic nanomaterials, thereby mitigating systemic non-specific immune response. For example, the s.c. administration of gelatin NPs (272 nm) cationized by quaternary amino groups to electrostatically load CpG oligonucleotides, a Toll-like receptor 9 (TLR9) ligand, led to their selective accumulation in dLNs over the spleen, resulting in the efficient activation of CpG-positive DCs in LNs, suppression of tumor growth, and prevention of splenic follicle destruction [<xref rid="B85-pharmaceutics-14-02752" ref-type="bibr">85</xref>]. In addition to NPs comprising organic materials, such as lipids and polymers [<xref rid="B84-pharmaceutics-14-02752" ref-type="bibr">84</xref>,<xref rid="B85-pharmaceutics-14-02752" ref-type="bibr">85</xref>,<xref rid="B86-pharmaceutics-14-02752" ref-type="bibr">86</xref>,<xref rid="B87-pharmaceutics-14-02752" ref-type="bibr">87</xref>], inorganic materials can be utilized to electrostatically load and deliver nucleotides and nucleic acids to the LNs for efficient anticancer immunotherapy. The benefits of inorganic NPs relative to organic NPs include the ease of tuning the size and surface charges and rendering additional functions, such as imaging, photothermal and photodynamic properties, and intrinsic adjuvant effects. For example, triethoxypropylaminosilane-functionalized silica NPs (SiNPs, 30 nm) [<xref rid="B88-pharmaceutics-14-02752" ref-type="bibr">88</xref>], polyethyleneimine (PEI)-functionalized mesoporous silica NPs (MSN, ~200 nm) [<xref rid="B89-pharmaceutics-14-02752" ref-type="bibr">89</xref>], and aluminum hydroxide NPs (~85 nm) [<xref rid="B90-pharmaceutics-14-02752" ref-type="bibr">90</xref>] were explored as CpG lymphatic delivery systems for efficient anticancer immunotherapy; however, their intrinsic adjuvant effects [<xref rid="B91-pharmaceutics-14-02752" ref-type="bibr">91</xref>] during delivery to the LNs need to be further investigated. The lymphatic transport mechanism of these rigid NPs with large sizes must also be investigated [<xref rid="B40-pharmaceutics-14-02752" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceutics-14-02752" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-14-02752" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-14-02752" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-14-02752" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-14-02752" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-14-02752" ref-type="bibr">46</xref>]. </p><p>In non-viral gene delivery systems, the size of polyplex NPs is inversely proportional to the multivalent electrostatic interactions governed by Coulomb&#8217;s Law. Short-length monomeric small interfering RNA (siRNA) resulted in NPs with a size of ~460 nm with linear PEI (LPEI). The formation of a multimerized siRNA through self-crosslinking between siRNA via reducible disulfide bonds could lead to NPs with a size of ~82 nm [<xref rid="B92-pharmaceutics-14-02752" ref-type="bibr">92</xref>]. The compact structures of NPs in multimerized siRNA are attributed to the higher charge density and more flexible structure than those of monomeric siRNA. Accordingly, polyplex NPs are often developed using multimerized nucleotide-based adjuvants for efficient lymphatic delivery. The Xiaoyuan Chen group utilized rolling circle amplification (RCA) to construct polymerized CpG with additional polymerized shRNA encoding signal transducer and activator of transcription 3 (<italic toggle="yes">Stat3</italic>) to suppress antigen-specific T cell tolerance [<xref rid="B93-pharmaceutics-14-02752" ref-type="bibr">93</xref>,<xref rid="B94-pharmaceutics-14-02752" ref-type="bibr">94</xref>]. Microflowers comprising poly(CpG) and poly(sh<italic toggle="yes">Stat3</italic>) can shrink from ~1200 nm to NPs of ~250 nm when complexed with positively charged PPT-<italic toggle="yes">g</italic>-PEG polymer, leading to efficient presentation of antigens on DCs (SIINFEKL<sup>+</sup> CD45<sup>+</sup>CD11c<sup>+</sup>) in LNs after i.l. administration (<xref rid="pharmaceutics-14-02752-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B93-pharmaceutics-14-02752" ref-type="bibr">93</xref>]. In another study, poly(CpG) microflowers were produced on primers conjugated to the PEG segments of PEG-PLA micelles, enabling the co-encapsulation of a hydrophobic peptide neoantigen to MC38 tumor (herein, adpgk) and a hydrophobic adjuvant (herein, a TLR 7/8 agonist R848) in the core of micelles [<xref rid="B94-pharmaceutics-14-02752" ref-type="bibr">94</xref>]. The resulting micelle-based microflowers containing poly(CpG), adpgk, and R848 with ~2200 nm size can be condensed into NPs with a size of ~170 nm when complexed with PPT-<italic toggle="yes">g</italic>-PEG. The resulting polyplex micelles were found to have higher LN accumulations than their free formulations following s.c. administration, ultimately leading to a higher expansion of LN-resident DCs (CD45<sup>+</sup>CD11c<sup>+</sup>) and macrophages (CD45<sup>+</sup>F4/80<sup>+</sup>), and systemic antigen-specific (dextramer<sup>+</sup>) CD8<sup>+</sup> T cells (CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup>), and efficient tumor regression [<xref rid="B94-pharmaceutics-14-02752" ref-type="bibr">94</xref>]. The combined administration of aPD-1 mAbs could also improve the therapeutic index [<xref rid="B94-pharmaceutics-14-02752" ref-type="bibr">94</xref>].</p></sec><sec id="sec2dot2dot3-pharmaceutics-14-02752"><title>2.2.3. DNA/RNA Engineering; Spherical Nucleic Acids (SNA) and DNA/RNA Origami</title><p>Spherical nucleic acids (SNAs), which were first introduced by Chad Mirkin&#8217;s group, comprise an NP core and a densely packed nucleic acid layer [<xref rid="B95-pharmaceutics-14-02752" ref-type="bibr">95</xref>]. SNAs exhibit distinguished properties from bare nucleic acids in terms of cellular uptake, stability against enzymatic degradation, and adsorption with endogenous biomolecules [<xref rid="B95-pharmaceutics-14-02752" ref-type="bibr">95</xref>,<xref rid="B96-pharmaceutics-14-02752" ref-type="bibr">96</xref>]. SNA with a 13 nm gold NP (AuNP) core and a CpG shell displayed significant accumulation in the subcapsular sinus of dLNs, but not in the parenchyma [<xref rid="B97-pharmaceutics-14-02752" ref-type="bibr">97</xref>]. Nevertheless, the CpG-decorated SNA induced the release of higher amounts of interleukin (IL)-12 from dLNs than free CpG, which significantly suppressed tumor growth when combined with an antigenic OVA protein or SIINFEKL peptides [<xref rid="B97-pharmaceutics-14-02752" ref-type="bibr">97</xref>]. In a study utilizing liposomal SNA (~120 nm) where cholesterol-modified DNA is embedded into the phospholipid membrane of core liposome (80&#8211;90 nm), the effects of liposomal membrane fluidity on lymphatic delivery of SNA were examined by varying the lipids with different phase transition temperature (T<sub>c</sub>) [<xref rid="B98-pharmaceutics-14-02752" ref-type="bibr">98</xref>]. Despite the identical NP size and surface chemistry, a liposomal SNA with higher T<sub>c</sub> accumulated in a higher quantity in dLNs than that with lower T<sub>c</sub> at an early time point (2 h after s.c. injection), which led to more efficient suppression of tumor growth [<xref rid="B98-pharmaceutics-14-02752" ref-type="bibr">98</xref>]. However, the accumulation of liposomal SNA was equivalent at 24 h, regardless of T<sub>c</sub> [<xref rid="B98-pharmaceutics-14-02752" ref-type="bibr">98</xref>]. As membrane fluidity is reversely proportional to T<sub>c</sub>, these results imply that a rigid core is beneficial in the rapid lymphatic delivery of SNA, followed by LNs-mediated anticancer immunotherapy. The James Moon groups reported a liposomal nanodisc, in which cholesterol-modified CpG was embedded on the surficial phospholipid membrane and cysteine-functionalized neoantigen peptides were chemically conjugated to the thiol-functionalized phospholipids (<xref rid="pharmaceutics-14-02752-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B99-pharmaceutics-14-02752" ref-type="bibr">99</xref>]. Nanodiscs injected s.c. facilitated higher accumulation of CpG and antigen peptides in the dLNs, enabling efficient antigen-specific (tetramer<sup>+</sup>) CD8<sup>+</sup> T-mediated anticancer therapy [<xref rid="B99-pharmaceutics-14-02752" ref-type="bibr">99</xref>]. As numerous kinds of core NPs can facilitate the loading of various hydrophobic and hydrophilic adjuvants and antigens, SNAs with various functions are expected to serve as a platform for lymphatic-mediated anticancer immunotherapy [<xref rid="B100-pharmaceutics-14-02752" ref-type="bibr">100</xref>,<xref rid="B101-pharmaceutics-14-02752" ref-type="bibr">101</xref>].</p><p>DNA and RNA have been exploited as building blocks for well-defined nanostructures owing to their Watson&#8211;Crick base pairing [<xref rid="B95-pharmaceutics-14-02752" ref-type="bibr">95</xref>,<xref rid="B102-pharmaceutics-14-02752" ref-type="bibr">102</xref>]. One of the interesting fields include DNA/RNA origamis that fold long single-stranded DNA/RNA scaffolds into an arbitrary structure using short DNA/RNA complementary to the scaffold as a staple [<xref rid="B102-pharmaceutics-14-02752" ref-type="bibr">102</xref>]. Previously, a DNA tetrahedron structure was demonstrated to display a higher accumulation in dLNs than double stranded linear DNA [<xref rid="B103-pharmaceutics-14-02752" ref-type="bibr">103</xref>]. The Baoquan Ding groups reported an interesting DNA nanodevice that enabled structural transformation from tubular to sheet under intracellular endosomal pH using DNA origami (<xref rid="pharmaceutics-14-02752-f003" ref-type="fig">Figure 3</xref>) [<xref rid="B104-pharmaceutics-14-02752" ref-type="bibr">104</xref>]. Multiple staple strands were utilized to fabricate a rectangle-shaped DNA origami from M13 bacteriophage DNA, which was further exploited to load tumor peptide antigen-DNA conjugates as an antigen and CpG and double-stranded RNA (dsRNA) as adjuvants via hybridization [<xref rid="B104-pharmaceutics-14-02752" ref-type="bibr">104</xref>]. pH-responsive DNA was also employed to hybridize the DNA in long edges of rectangle-shaped DNA origami, enabling the formation of a tubular nanostructure with diameter and length of ~19 nm and ~90 nm, respectively, and pH-responsive transformation [<xref rid="B104-pharmaceutics-14-02752" ref-type="bibr">104</xref>]. Compared to the physical mixture of therapeutics, including peptide antigens, CpG, and dsRNA, the resulting DNA nanodevices could drain into dLNs ~5 times more, eliciting higher expansion and activation (CD86<sup>+</sup>) of DCs (CD45<sup>+</sup>CD11c<sup>+</sup>), followed by enrichment of antigen-specific (tetramer<sup>+</sup>) CTL (IFN-&#947;+ CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup>) [<xref rid="B104-pharmaceutics-14-02752" ref-type="bibr">104</xref>]. Accordingly, robust antitumor immunotherapy in various tumor models, including MC38, B16F10, and B16F10-OVA, was achieved [<xref rid="B104-pharmaceutics-14-02752" ref-type="bibr">104</xref>].</p></sec><sec id="sec2dot2dot4-pharmaceutics-14-02752"><title>2.2.4. Self-Assembled or Recombinant Protein</title><p>In addition to their general therapeutic roles, including as antigens or therapeutic antibodies, proteins can serve as a lymphatic drug delivery platform. Owing to size-dependent LN accumulation, self-assembled OVA NPs (~80 nm) were developed by cleaving the disulfide bonds of an OVA antigen protein to change its charges to positive and then complex it with CpG [<xref rid="B105-pharmaceutics-14-02752" ref-type="bibr">105</xref>]. Coordination among OVA antigen proteins, manganese (Mn<sup>2+</sup>), and meso-2,6-diaminopimelic acid (DAP) was found to facilitate the preparation of nanocomposites with a size of 150 nm [<xref rid="B106-pharmaceutics-14-02752" ref-type="bibr">106</xref>]. The increased size of these self-assembled antigen NPs led to a significantly higher LN accumulation of antigens than bare antigen proteins [<xref rid="B105-pharmaceutics-14-02752" ref-type="bibr">105</xref>,<xref rid="B106-pharmaceutics-14-02752" ref-type="bibr">106</xref>], followed by successful suppression of tumor growth [<xref rid="B106-pharmaceutics-14-02752" ref-type="bibr">106</xref>]. </p><p>Proteins vary in size, 3D structures, and surface characteristics, which critically affect lymphatic delivery. Advances in genetic recombination and protein engineering technology enable not only the preparation of recombinant proteins to present antigens or antibodies but also the tuning of physicochemical properties for self-assembly. Lee et al. demonstrated that human ferritin (hFTN, ~11 nm) exhibited a 3-to-7-fold higher accumulation than <italic toggle="yes">Escherichia coli</italic> DNA binding protein (DPS, 9.5 nm), <italic toggle="yes">Thermoplasma acidophilum</italic> proteasome (PTS, 13.4 nm), and Hepatitis B virus capsid (HBVC, 32.3 nm) [<xref rid="B107-pharmaceutics-14-02752" ref-type="bibr">107</xref>]. Genetic fusion of RFP and hFTN subunits afforded an engineered hFTN to present a model tumor antigen (herein, red-fluorescence protein (RFP)), which induced conformational changes in proteins. The diameter of the engineered hFTN increased to ~22 nm. The hFTN-RFP protein NPs efficiently drained into the LNs, inducing efficient antitumor immunotherapy against RFP-expressing tumor-bearing models [<xref rid="B107-pharmaceutics-14-02752" ref-type="bibr">107</xref>]. Owing to the efficient lymphatic transport of hFTN, Kim et al. developed hFTN fusion proteins to present a PD-1 (<xref rid="pharmaceutics-14-02752-f004" ref-type="fig">Figure 4</xref>) [<xref rid="B108-pharmaceutics-14-02752" ref-type="bibr">108</xref>]. The resultant nano-cages had a larger size (~22 nm) than wild-type hFTN (wtNCs, ~13 nm), and they displayed not only a higher affinity against PD-L1 and PD-L2 than soluble PD-1 (sPD-1) but also higher accumulation in dLNs than the monomeric form of sPD-1 and wtNCs. Accordingly, efficient activation (CD86<sup>+</sup>, CD40<sup>+</sup>) of DCs (CD45<sup>+</sup>CD11c<sup>+</sup>) and CD8<sup>+</sup> T (CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup>) cells-mediated inhibition of tumor growth occurred [<xref rid="B108-pharmaceutics-14-02752" ref-type="bibr">108</xref>]. A further study to examine the mechanism whereby the properties of hFTN facilitate the efficient lymphatic delivery is expected to contribute to the development of advanced lymphatic delivery systems using protein scaffolds.</p></sec><sec id="sec2dot2dot5-pharmaceutics-14-02752"><title>2.2.5. Chemical Conjugation</title><p>Drugs with functional groups that can participate in a chemical reaction can be conjugated to various drug delivery systems, including iron oxide NPs, quantum dots, graphene oxide, liposomes, micelles, etc. [<xref rid="B109-pharmaceutics-14-02752" ref-type="bibr">109</xref>,<xref rid="B110-pharmaceutics-14-02752" ref-type="bibr">110</xref>,<xref rid="B111-pharmaceutics-14-02752" ref-type="bibr">111</xref>,<xref rid="B112-pharmaceutics-14-02752" ref-type="bibr">112</xref>,<xref rid="B113-pharmaceutics-14-02752" ref-type="bibr">113</xref>]. Examples include conjugations of CpG and si<italic toggle="yes">Stat3</italic> to linkers on the quantum dots (~150 nm) via a disulfide bond [<xref rid="B109-pharmaceutics-14-02752" ref-type="bibr">109</xref>], amide conjugations of antigen peptides to lipids to enable hydrophobic interactions with oleic acids on iron oxide NPs (30&#8211;45 nm) [<xref rid="B110-pharmaceutics-14-02752" ref-type="bibr">110</xref>], amide conjugations of antigen peptides to PEG-(poly(maleic anhydride-alt-1-octadecene)) loaded on graphene oxide (20&#8211;30 nm) via hydrophobic interactions [<xref rid="B111-pharmaceutics-14-02752" ref-type="bibr">111</xref>], conjugations of antigen peptides to lipids comprising liposomes (~23 nm) via an amide bond [<xref rid="B112-pharmaceutics-14-02752" ref-type="bibr">112</xref>], and conjugations of antigen peptides to poly(L-histidine)-poly(ethylene glycol) micelles (~60 nm) via a disulfide bond [<xref rid="B113-pharmaceutics-14-02752" ref-type="bibr">113</xref>], ultimately leading to a high accumulation of immunomodulatory drugs in the LNs, followed by efficient antitumor immunotherapy. The other examples are discussed in overall manuscript.</p></sec></sec><sec id="sec2dot3-pharmaceutics-14-02752"><title>2.3. Advanced NPs for Active Transport to the LNs</title><p>In contrast to passive transport, active transport involves the lymphatic transport of cargos via immune cells. In particular, peripheral DCs encountered immuno-stimulatory agents and antigens can initiate adaptive antitumor immune response in dLNs owing to the intrinsic lymph-homing ability of maturating and activating APCs. A representative strategy involves the construction or functionalization of NPs with mannose &amp; mannan, or hyaluronic acid &amp; hyaluronan with mannose-receptors or CD44, respectively, which are expressed on the surfaces of APCs, such as DCs and macrophages [<xref rid="B56-pharmaceutics-14-02752" ref-type="bibr">56</xref>,<xref rid="B57-pharmaceutics-14-02752" ref-type="bibr">57</xref>,<xref rid="B58-pharmaceutics-14-02752" ref-type="bibr">58</xref>,<xref rid="B59-pharmaceutics-14-02752" ref-type="bibr">59</xref>,<xref rid="B60-pharmaceutics-14-02752" ref-type="bibr">60</xref>,<xref rid="B61-pharmaceutics-14-02752" ref-type="bibr">61</xref>,<xref rid="B62-pharmaceutics-14-02752" ref-type="bibr">62</xref>,<xref rid="B63-pharmaceutics-14-02752" ref-type="bibr">63</xref>,<xref rid="B64-pharmaceutics-14-02752" ref-type="bibr">64</xref>,<xref rid="B114-pharmaceutics-14-02752" ref-type="bibr">114</xref>,<xref rid="B115-pharmaceutics-14-02752" ref-type="bibr">115</xref>,<xref rid="B116-pharmaceutics-14-02752" ref-type="bibr">116</xref>,<xref rid="B117-pharmaceutics-14-02752" ref-type="bibr">117</xref>]. Ligand-mediated improvement of the lymphatic delivery of cargos was clearly demonstrated with mannose-decorated liposomes (~160 nm) loading poly(I:C) electrostatically [<xref rid="B56-pharmaceutics-14-02752" ref-type="bibr">56</xref>], tumor cell lysate-loaded chitosan NPs (~120 nm) functionalized with mannose [<xref rid="B114-pharmaceutics-14-02752" ref-type="bibr">114</xref>], micelles (~95 nm) comprising stearic acid-grafted and mannose-modified chitosan [<xref rid="B115-pharmaceutics-14-02752" ref-type="bibr">115</xref>], NPs (~310 nm) comprising alginates grafting mannose and OVA proteins [<xref rid="B116-pharmaceutics-14-02752" ref-type="bibr">116</xref>], mannose-functionalized pH-sensitive micelles (30&#8211;50 nm) loading antigens via disulfide bonds [<xref rid="B117-pharmaceutics-14-02752" ref-type="bibr">117</xref>], and TLR7/8 agonists and OVA proteins loaded poly(lactide-co-glycolide) (PLGA) NPs (~225 nm), whose surface was emulsified with hyaluronic acid [<xref rid="B62-pharmaceutics-14-02752" ref-type="bibr">62</xref>]. Of note, in these NPs, the size-dependent passive transport mechanisms cannot be omitted from the uptake of drugs and NPs in lymph-homing APCs and APCs-mediated CD8<sup>+</sup> T cell instructions in LNs. Indeed, by comparing a mannan nanocapsule and a silica NP decorated with mannan, a higher quantity of nanocapsule was found to be accumulated in the dLNs than that of silica NPs, despite similar zeta potential and size (both ~220 nm). These results were ascribed to the high deformability of nanocapsules to pass through a 50&#8211;100 nm pore-sized membrane; silica NPs cannot efficiently pass through such membrane [<xref rid="B61-pharmaceutics-14-02752" ref-type="bibr">61</xref>]. The study findings also implied the partial, but significant contribution of passive lymphatic transport pathways, even in the case of NPs decorated with ligands, to the interaction with lymph-homing APCs.</p><p>The intrinsic biocompatibility of mammalian cell membranes has promoted the development of membrane-cloaked NPs for efficient lymphatic delivery and antitumor immunotherapy [<xref rid="B118-pharmaceutics-14-02752" ref-type="bibr">118</xref>]. For example, red blood cell (RBC) membranes for the camouflage of PLGA NPs chemically loading antigenic peptide (herein hgp100<sub>25&#8211;33</sub>) were modified with mannose (~160 nm) by embedding lipids-PEG-mannose to improve lymphatic active transport of the NPs [<xref rid="B119-pharmaceutics-14-02752" ref-type="bibr">119</xref>]. Compared to the controls, including PLGA NPs and RBC-cloaked PLGA NPs, the mannose-RBC-cloaked PLGA NPs were more susceptible to uptake by APCs and accumulation into dLNs, and induced more efficient CD8<sup>+</sup> T (CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup>) cell-mediated antitumor effects after i.d. administration [<xref rid="B119-pharmaceutics-14-02752" ref-type="bibr">119</xref>]. In this regard, cancer cell membranes containing tumor-associated antigens could be exploited as a substitute for biomaterials containing mammalian cell membranes and antigens [<xref rid="B120-pharmaceutics-14-02752" ref-type="bibr">120</xref>]. In particular, DC membranes containing CCR7, L-selectin, and integrins can be an interesting source for camouflaging NPs to exhibit homologous targeting to LNs [<xref rid="B121-pharmaceutics-14-02752" ref-type="bibr">121</xref>]. Indeed, functionalization with DC membranes significantly promoted the LN accumulation of OVA protein-loading micelles synthesized using stearic acid- and histidine-grafted chitosan polymers (~150 nm), and improved the activation (CD86<sup>+</sup> and CD40<sup>+</sup>) of DCs (CD45<sup>+</sup>CD11c<sup>+</sup>) in dLNs and expansion of CD8<sup>+</sup> T cells (CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup>) in tumors [<xref rid="B121-pharmaceutics-14-02752" ref-type="bibr">121</xref>]. DC membranes can be engineered to present antigens on major histocompatibility complex (MHC) and CD28 co-stimulator before being used for cloaking NPs (<xref rid="pharmaceutics-14-02752-f005" ref-type="fig">Figure 5</xref>) [<xref rid="B122-pharmaceutics-14-02752" ref-type="bibr">122</xref>]. Further functionalization of matured DC membrane-camouflaged NPs (~180 nm) with CD3 antibodies was reported to enable significant regression of tumor growth owing to efficient lymphatic accumulation and retention of NPs via the combined lymph-homing effects of DC membranes and T cell binding effects of the CD3 antibodies [<xref rid="B122-pharmaceutics-14-02752" ref-type="bibr">122</xref>]. The resultant NPs containing imiquimod led to efficient antitumor effects, with significant activation of DCs (CD45<sup>+</sup>CD11c<sup>+</sup> CD80<sup>+</sup>CD86<sup>+</sup>) and macrophages (CD80<sup>hi</sup> CD45<sup>+</sup>CD11b<sup>+</sup>F4/80<sup>+</sup>) and expansion of CD8<sup>+</sup> T cells (CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup>) [<xref rid="B122-pharmaceutics-14-02752" ref-type="bibr">122</xref>]. Based on these criteria, fused membranes from DCs and cancer cells have been explored in the development of membrane-cloaked NPs for antitumor immunotherapy [<xref rid="B123-pharmaceutics-14-02752" ref-type="bibr">123</xref>,<xref rid="B124-pharmaceutics-14-02752" ref-type="bibr">124</xref>]. </p><p>Numerous studies have exploited the extracellular vesicles (EVs) secreted from various cell types as a drug delivery platform and therapeutic, as EVs contain miRNA, bioactive lipids, and proteins that can control intercellular communications [<xref rid="B125-pharmaceutics-14-02752" ref-type="bibr">125</xref>]. As EVs are formed through fusion of the cell vacuole with cell membranes, they can contain various membrane proteins on their surface. Accordingly, EVs from matured and activated APCs could elicit LN-homing ability and immuno-stimulatory functions in antitumor immunotherapy [<xref rid="B126-pharmaceutics-14-02752" ref-type="bibr">126</xref>,<xref rid="B127-pharmaceutics-14-02752" ref-type="bibr">127</xref>]. Indeed, EVs released from DCs maturated and activated by OVA antigens and poly(I:C) (30&#8211;100 nm) were revealed to contain CD80 and MHC, which stimulate the activation (CD69<sup>+</sup>) of CD8<sup>+</sup> T cells (CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup>). The EVs could efficiently drain into LNs, and their efficacy was improved with a CTLA-4 mAb decoration on the membranes by anchoring lipids-PEG-aCTLA-4 (<xref rid="pharmaceutics-14-02752-f006" ref-type="fig">Figure 6</xref>) [<xref rid="B126-pharmaceutics-14-02752" ref-type="bibr">126</xref>]. In particular, the resulting aCTLA-4 decorated EVs enabled long-term antitumor immunotherapy with effector memory T cells (CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup>CD44<sup>+</sup>CD62L<sup>-</sup>) [<xref rid="B126-pharmaceutics-14-02752" ref-type="bibr">126</xref>]. Similarly, EVs purified from M1 macrophages polarized by LPS and IFN interferon-&#947; (IFN-&#947;) (50 nm) [<xref rid="B127-pharmaceutics-14-02752" ref-type="bibr">127</xref>] displayed significant LNs accumulation, induced the release of proinflammatory cytokines (IL-6) in dLNs, and elicited antitumor immunotherapeutic effects when co-treated with antigens.</p></sec><sec id="sec2dot4-pharmaceutics-14-02752"><title>2.4. Advanced NPs for Deeper Access to the LNs</title><p>After transport to the LNs, immuno-modulatory drugs should access the LN parenchyma where adaptive immune cells reside. However, LN conduits and cortex function as size-dependent exclusion barriers to allow access to solutes that are less than 70 kDa (~several nm in size) [<xref rid="B73-pharmaceutics-14-02752" ref-type="bibr">73</xref>], which could lead to a size conflict for efficient passive transport [<xref rid="B40-pharmaceutics-14-02752" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceutics-14-02752" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-14-02752" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-14-02752" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-14-02752" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-14-02752" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-14-02752" ref-type="bibr">46</xref>]. The Susan N. Thomas groups reported a multistage drug delivery system comprising a 30 nm pluronic F127 micelle (30 nm), whose core was stabilized with physically entangled PPS and shell was decorated with a CpG via a linker to exhibit first order degradation independent of pH and solvents (<xref rid="pharmaceutics-14-02752-f007" ref-type="fig">Figure 7</xref>) [<xref rid="B128-pharmaceutics-14-02752" ref-type="bibr">128</xref>]. This size change for the cargo allowed the drug-conjugating NPs to efficiently drain into the LNs via size-dependent passive transport and subsequently deliver drugs to the LN parenchyma [<xref rid="B128-pharmaceutics-14-02752" ref-type="bibr">128</xref>]. Owing to the efficient delivery of CpG into the LN parenchyma, higher activation (CD40<sup>+</sup> and/or CD86<sup>+</sup>) of conventional DCs (cDCs, CD45<sup>+</sup>CD11c<sup>+</sup>B220<sup>-</sup>), plasmacytoid DCs (pDCs, CD45<sup>+</sup>CD11c<sup>+</sup>B220<sup>+</sup>), and B cells (CD45+CD11b<sup>-</sup>CD3<sup>-</sup>B220<sup>+</sup>) was observed with NPs with multistage drug delivery compared to that with the controls [<xref rid="B128-pharmaceutics-14-02752" ref-type="bibr">128</xref>]. Accordingly, higher expansion of T cells (CD45<sup>+</sup>CD3<sup>+</sup>B220<sup>-</sup>), which significantly suppressed EL-4 lymphoma tumor growth in LNs, was recorded [<xref rid="B128-pharmaceutics-14-02752" ref-type="bibr">128</xref>]. This strategy outlines an approach to re-purpose numerous trojan horse and size-transformable NPs previously reported for deep penetration into the tumor tissues [<xref rid="B129-pharmaceutics-14-02752" ref-type="bibr">129</xref>,<xref rid="B130-pharmaceutics-14-02752" ref-type="bibr">130</xref>,<xref rid="B131-pharmaceutics-14-02752" ref-type="bibr">131</xref>] for LNs-mediated anticancer immunotherapy.</p></sec></sec><sec id="sec3-pharmaceutics-14-02752"><title>3. Advanced HGs for LNs Accumulation and Adaptive Cancer Immunotherapy</title><p>According to numerous reports, i.t. administration of HGs facilitates the sustained release of incorporated immunotherapeutics into tumor microenvironments, enabling efficient and/or prolonged anticancer immune responses in tumors [<xref rid="B132-pharmaceutics-14-02752" ref-type="bibr">132</xref>,<xref rid="B133-pharmaceutics-14-02752" ref-type="bibr">133</xref>,<xref rid="B134-pharmaceutics-14-02752" ref-type="bibr">134</xref>,<xref rid="B135-pharmaceutics-14-02752" ref-type="bibr">135</xref>,<xref rid="B136-pharmaceutics-14-02752" ref-type="bibr">136</xref>,<xref rid="B137-pharmaceutics-14-02752" ref-type="bibr">137</xref>,<xref rid="B138-pharmaceutics-14-02752" ref-type="bibr">138</xref>,<xref rid="B139-pharmaceutics-14-02752" ref-type="bibr">139</xref>,<xref rid="B140-pharmaceutics-14-02752" ref-type="bibr">140</xref>,<xref rid="B141-pharmaceutics-14-02752" ref-type="bibr">141</xref>,<xref rid="B142-pharmaceutics-14-02752" ref-type="bibr">142</xref>,<xref rid="B143-pharmaceutics-14-02752" ref-type="bibr">143</xref>,<xref rid="B144-pharmaceutics-14-02752" ref-type="bibr">144</xref>,<xref rid="B145-pharmaceutics-14-02752" ref-type="bibr">145</xref>,<xref rid="B146-pharmaceutics-14-02752" ref-type="bibr">146</xref>,<xref rid="B147-pharmaceutics-14-02752" ref-type="bibr">147</xref>,<xref rid="B148-pharmaceutics-14-02752" ref-type="bibr">148</xref>,<xref rid="B149-pharmaceutics-14-02752" ref-type="bibr">149</xref>,<xref rid="B150-pharmaceutics-14-02752" ref-type="bibr">150</xref>,<xref rid="B151-pharmaceutics-14-02752" ref-type="bibr">151</xref>,<xref rid="B152-pharmaceutics-14-02752" ref-type="bibr">152</xref>,<xref rid="B153-pharmaceutics-14-02752" ref-type="bibr">153</xref>,<xref rid="B154-pharmaceutics-14-02752" ref-type="bibr">154</xref>,<xref rid="B155-pharmaceutics-14-02752" ref-type="bibr">155</xref>,<xref rid="B156-pharmaceutics-14-02752" ref-type="bibr">156</xref>,<xref rid="B157-pharmaceutics-14-02752" ref-type="bibr">157</xref>,<xref rid="B158-pharmaceutics-14-02752" ref-type="bibr">158</xref>,<xref rid="B159-pharmaceutics-14-02752" ref-type="bibr">159</xref>,<xref rid="B160-pharmaceutics-14-02752" ref-type="bibr">160</xref>,<xref rid="B161-pharmaceutics-14-02752" ref-type="bibr">161</xref>,<xref rid="B162-pharmaceutics-14-02752" ref-type="bibr">162</xref>,<xref rid="B163-pharmaceutics-14-02752" ref-type="bibr">163</xref>,<xref rid="B164-pharmaceutics-14-02752" ref-type="bibr">164</xref>] or tumors and TdLNs [<xref rid="B165-pharmaceutics-14-02752" ref-type="bibr">165</xref>,<xref rid="B166-pharmaceutics-14-02752" ref-type="bibr">166</xref>,<xref rid="B167-pharmaceutics-14-02752" ref-type="bibr">167</xref>,<xref rid="B168-pharmaceutics-14-02752" ref-type="bibr">168</xref>,<xref rid="B169-pharmaceutics-14-02752" ref-type="bibr">169</xref>]. The immunotherapeutics released from HGs in a sustained manner would also accumulate in the TdLNs. Some studies attempted to determine the effects of sustained release on the lymphatic accumulation of immunotherapeutics, immuno-modulations in LNs, and overall therapeutic effects [<xref rid="B31-pharmaceutics-14-02752" ref-type="bibr">31</xref>,<xref rid="B170-pharmaceutics-14-02752" ref-type="bibr">170</xref>,<xref rid="B171-pharmaceutics-14-02752" ref-type="bibr">171</xref>,<xref rid="B172-pharmaceutics-14-02752" ref-type="bibr">172</xref>]. An HG prepared via crosslinking between aldehyde-functionalized mannan and <italic toggle="yes">N, O</italic>-carboxymethyl chitosan led to higher accumulations of OVA antigens in dLN at 24 h and 48 h after its locoregional s.c. administration than free OVA and Alum/OVA formulations, which promoted and prolonged the production of antigen-specific immunoglobulin G (IgG), despite a slight delay in tumor growth [<xref rid="B170-pharmaceutics-14-02752" ref-type="bibr">170</xref>]. In addition, mPEG-<italic toggle="yes">b</italic>-poly(<sub>L</sub>-valine) HGs prolonged and enhanced the lymphatic accumulation of tumor cell lysates that were incorporated in the HGs and released from the injection sites (<xref rid="pharmaceutics-14-02752-f008" ref-type="fig">Figure 8</xref>) [<xref rid="B171-pharmaceutics-14-02752" ref-type="bibr">171</xref>]. Accordingly, significant activation (MHCII<sup>+</sup>, CD86<sup>+</sup>) of DCs (CD45<sup>+</sup>CD11c<sup>+</sup>) in dLNs and expansion of CD8<sup>+</sup> T cells (CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup>) in dLNs, spleen, and tumors were achieved when poly(I:C) and tumor cell lysates were incorporated in the HGs administered s.c. to the tissue i.l. to the tumor [<xref rid="B171-pharmaceutics-14-02752" ref-type="bibr">171</xref>]. Compared to the control with free formulations, tumor growth could be significantly delayed with HG [<xref rid="B171-pharmaceutics-14-02752" ref-type="bibr">171</xref>]. Similarly, silk HGs administered s.c. to the tissue i.l. to the tumor facilitated improved accumulation of the immunotherapeutics (herein, neoantigens, CpG, and STING agonist 2, 3-cyclic-GMP-AMP (cGAMP)) in dLNs, leading to significant suppression of tumor growth with the expansion of activated DCs (CD86<sup>+</sup>CD80<sup>+</sup> CD45<sup>+</sup>CD11c<sup>+</sup>) in dLNs and activated CD8<sup>+</sup> T cells (41BB<sup>+</sup> CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup>) in tumors [<xref rid="B172-pharmaceutics-14-02752" ref-type="bibr">172</xref>]. These studies highlight the importance of the pharmacokinetics of immunotherapeutic drugs in LNs, where adaptive immune responses mainly occur. However, the mechanism whereby HG-mediated sustained release improves lymphatic accumulations of cargos has not been clearly revealed.</p></sec><sec id="sec4-pharmaceutics-14-02752"><title>4. Hybrid HGs and NPs for LNs Targeting and Adaptive Cancer Immunotherapy</title><p>Hybrid systems have been developed to exploit the potential of HGs and NPs for improved accumulation of immunotherapeutics in LNs. Yin et al. mixed graphene oxide (GO, ~200 nm) with linear PEI (LPEI) to form HGs encapsulating R848 via &#960;&#8722;&#960; stacking with GO and OVA-mRNA via electrostatic interactions with LPEI [<xref rid="B173-pharmaceutics-14-02752" ref-type="bibr">173</xref>]. HG-released NPs (~220 nm) formulated via an electrostatic interaction between R848-loaded GO (negative charges) and OVA-mRNA/LPEI polyplex (positive charges), were released in a sustained manner, and led to markedly higher uptake of cargos into the dLNs when injected s.c. [<xref rid="B173-pharmaceutics-14-02752" ref-type="bibr">173</xref>]. The prolonged lymphatic delivery of R848 and OVA-mRNA resulted in the most efficient tumor suppression with CTLs (IFN-&#947;<sup>+</sup> CD45<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup>) compared to that of the controls, including saline, free R848 and OVA-mRNA, and OVA-mRNA-loaded HG [<xref rid="B173-pharmaceutics-14-02752" ref-type="bibr">173</xref>]. Our group reported a novel polymeric HG to release drug-loaded micelles in situ without using additional NPs (<xref rid="pharmaceutics-14-02752-f009" ref-type="fig">Figure 9</xref>) [<xref rid="B174-pharmaceutics-14-02752" ref-type="bibr">174</xref>]. F127-Gelatin was prepared by crosslinking F127 to gelatin, which increased the hydrophobicity, enabling the formation of a thermosensitive HG at very low concentrations (4&#8211;7 wt.%) compared with the precursor F127 (&gt;15 wt.%) [<xref rid="B174-pharmaceutics-14-02752" ref-type="bibr">174</xref>]. Interestingly, the F127-Gelatin polymers comprising thermosensitive HGs were released as micelles (~30 nm) loaded with aCTLA-4 mAb in a sustained manner [<xref rid="B174-pharmaceutics-14-02752" ref-type="bibr">174</xref>]. Sustained release and a size appropriate for passive lymphatic transport facilitated the efficient and prolonged accumulation of aCTLA-4 mAb, ultimately enabling efficient anticancer immunotherapy [<xref rid="B174-pharmaceutics-14-02752" ref-type="bibr">174</xref>]. The concept of NPs and HG hybrid systems is expected to be more extensively explored for efficient locoregional anticancer immunotherapy in the near future.</p></sec><sec sec-type="conclusions" id="sec5-pharmaceutics-14-02752"><title>5. Conclusions and Perspectives</title><p>From a traditional pharmaceutical perspective, anticancer drugs and their delivery formulations are mainly systemically administered to selectively reach metastatic tumors or deep tumor tissues during blood circulation. Locoregional administration via the i.t. route is occasionally employed to mitigate off-target systemic delivery and improve tumoral accumulations of drugs when tumors are located to be easily accessed to the treatment. </p><p>Advances in biotechnology and expanded knowledge on immunology help highlight lymphatic systems as important targets for adaptive anticancer immunotherapy. However, the systemic administration routes have limitations, such as inefficient lymphatic delivery compared to locoregional delivery [<xref rid="B5-pharmaceutics-14-02752" ref-type="bibr">5</xref>,<xref rid="B31-pharmaceutics-14-02752" ref-type="bibr">31</xref>]. Accordingly, in this review, we discussed emerging locoregional drug delivery strategies that target lymphoid tissues instead of tumor and tumor microenvironments for cancer immunotherapy. The physiology of lymphatic systems motivate the use of NPs for the accumulation of immuno-modulatory drugs at LNs, where adaptive immune responses mainly occur, especially via passive lymphatic transport mechanisms. Further, sophisticated engineering of NPs facilitates the exploitation of active lymphatic transport pathways of cargos, which utilize the intrinsic lymph-homing ability of peripheral APCs. In addition to NPs, HGs that release drugs in a sustained manner have demonstrated benefits such as improved, efficient, and prolonged lymphatic accumulation of drugs, avoidance of repeated administrations, and achievement of dose sparing, thereby leading to efficient anticancer immunotherapy. However, the mechanisms associated with sustained locoregional release and lymphatic drainage need to be further addressed. In particular, hybrid NP and HG systems have been explored as a potential platform to combine the benefits of both NPs and HGs. </p><p>There are several issues to be addressed in locoregional anticancer immunotherapy targeting LNs. First, several tumors lack tertiary lymphoid structures [<xref rid="B175-pharmaceutics-14-02752" ref-type="bibr">175</xref>,<xref rid="B176-pharmaceutics-14-02752" ref-type="bibr">176</xref>,<xref rid="B177-pharmaceutics-14-02752" ref-type="bibr">177</xref>,<xref rid="B178-pharmaceutics-14-02752" ref-type="bibr">178</xref>] where are primary target tissues of locoregional anticancer immunotherapy to instruct and expand effector immune cells. Second, although locoregional delivery allows immune responses specific to the tumors and dLNs and mitigates the systemic immune-related adverse toxicity, it is unclear whether it is beneficial to the treatment of metastatic tumors, compared to systemic delivery to allow the wide distribution of cargos to various LNs presented throughout the body [<xref rid="B179-pharmaceutics-14-02752" ref-type="bibr">179</xref>,<xref rid="B180-pharmaceutics-14-02752" ref-type="bibr">180</xref>,<xref rid="B181-pharmaceutics-14-02752" ref-type="bibr">181</xref>]. Therefore, innovations in the design of NPs and HGs for lymphatic delivery and further investigations to address the issues would maximize therapeutic effectiveness, improve patient compliance, and increase safety in the clinic through locoregional anticancer immunotherapy. </p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Investigation and writing&#8212;original draft preparation, K.J.C. and J.K., writing&#8212;review and editing, and validation, Y.-E.C. and J.K., and supervision, J.K. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable. </p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-14-02752"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nam</surname><given-names>J.</given-names></name><name name-style="western"><surname>Son</surname><given-names>S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shea</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>J.J.</given-names></name></person-group><article-title>Cancer nanomedicine for combination cancer immunotherapy</article-title><source>Nat. Rev. Mater.</source><year>2019</year><volume>4</volume><fpage>398</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1038/s41578-019-0108-1</pub-id></element-citation></ref><ref id="B2-pharmaceutics-14-02752"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Saw</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Song</surname><given-names>E.</given-names></name></person-group><article-title>Turning cold tumors hot: From molecular mechanisms to clinical applications</article-title><source>Trends Immunol.</source><year>2022</year><volume>43</volume><fpage>524</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1016/j.it.2022.04.010</pub-id><pub-id pub-id-type="pmid">35624021</pub-id></element-citation></ref><ref id="B3-pharmaceutics-14-02752"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Francis</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name></person-group><article-title>Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy</article-title><source>Adv. Drug Deliv. Rev.</source><year>2017</year><volume>114</volume><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2017.04.011</pub-id><pub-id pub-id-type="pmid">28455187</pub-id><pub-id pub-id-type="pmcid">PMC5581991</pub-id></element-citation></ref><ref id="B4-pharmaceutics-14-02752"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Manspeaker</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name></person-group><article-title>Augmenting the synergies of chemotherapy and immunotherapy through drug delivery</article-title><source>Acta Biomater.</source><year>2019</year><volume>88</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2019.02.012</pub-id><pub-id pub-id-type="pmid">30769136</pub-id></element-citation></ref><ref id="B5-pharmaceutics-14-02752"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manspeaker</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>O&#8217;Melia</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name></person-group><article-title>Elicitation of stem-like CD8<sup>+</sup> T cell responses via lymph node-targeted chemoimmunotherapy evokes systemic tumor control</article-title><source>J. Immunother. Cancer</source><year>2022</year><volume>10</volume><fpage>e005079</fpage><pub-id pub-id-type="doi">10.1136/jitc-2022-005079</pub-id><pub-id pub-id-type="pmid">36100312</pub-id><pub-id pub-id-type="pmcid">PMC9472119</pub-id></element-citation></ref><ref id="B6-pharmaceutics-14-02752"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fucikova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kepp</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kasikova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Petroni</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Spisek</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Galluzzi</surname><given-names>L.</given-names></name></person-group><article-title>Detection of immunogenic cell death and its relevance for cancer therapy</article-title><source>Cell Death Dis.</source><year>2020</year><volume>11</volume><fpage>1013</fpage><pub-id pub-id-type="doi">10.1038/s41419-020-03221-2</pub-id><pub-id pub-id-type="pmid">33243969</pub-id><pub-id pub-id-type="pmcid">PMC7691519</pub-id></element-citation></ref><ref id="B7-pharmaceutics-14-02752"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Piao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name></person-group><article-title>Co-delivery of IOX1 and doxorubicin for antibodyindependent cancer chemo-immunotherapy</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>2425</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-22407-6</pub-id><pub-id pub-id-type="pmid">33893275</pub-id><pub-id pub-id-type="pmcid">PMC8065121</pub-id></element-citation></ref><ref id="B8-pharmaceutics-14-02752"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>Y.-P.</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>1811</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-01651-9</pub-id><pub-id pub-id-type="pmid">29180759</pub-id><pub-id pub-id-type="pmcid">PMC5703845</pub-id></element-citation></ref><ref id="B9-pharmaceutics-14-02752"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pol</surname><given-names>J.</given-names></name><name name-style="western"><surname>Levesque</surname><given-names>S.</given-names></name><name name-style="western"><surname>Petrazzuolo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pfirschke</surname><given-names>C.</given-names></name><name name-style="western"><surname>Engblom</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rickelt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Iribarren</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Crizotinib-induced immunogenic cell death in non-small cell lung cancer</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>1486</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-09415-3</pub-id><pub-id pub-id-type="pmid">30940805</pub-id><pub-id pub-id-type="pmcid">PMC6445096</pub-id></element-citation></ref><ref id="B10-pharmaceutics-14-02752"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imbert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Montfort</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fraisse</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marcheteau</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gilhodes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bertrand</surname><given-names>F.</given-names></name><name name-style="western"><surname>Marcellin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burlet-Schiltz</surname><given-names>O.</given-names></name><name name-style="western"><surname>de Peredo</surname><given-names>A.G.</given-names></name><etal/></person-group><article-title>Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>437</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-14218-7</pub-id><pub-id pub-id-type="pmid">31974367</pub-id><pub-id pub-id-type="pmcid">PMC6978345</pub-id></element-citation></ref><ref id="B11-pharmaceutics-14-02752"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rivas</surname><given-names>E.I.</given-names></name><name name-style="western"><surname>Linares</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zwick</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gomez-Llonin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guiu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Labernadie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Badia-Ramentol</surname><given-names>J.</given-names></name><name name-style="western"><surname>Llado</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bardia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Perez-Nunez</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>5310</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-32782-3</pub-id><pub-id pub-id-type="pmid">36085201</pub-id><pub-id pub-id-type="pmcid">PMC9463158</pub-id></element-citation></ref><ref id="B12-pharmaceutics-14-02752"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>L.-T.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Oguz</surname><given-names>G.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goh</surname><given-names>J.Y.</given-names></name><etal/></person-group><article-title>Hypoxia induces HIF1&#945;-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>4118</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-31764-9</pub-id><pub-id pub-id-type="pmid">35840558</pub-id><pub-id pub-id-type="pmcid">PMC9287350</pub-id></element-citation></ref><ref id="B13-pharmaceutics-14-02752"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Glucocorticoid receptor regulates PD-L1 and MHCI in pancreatic cancer cells to promote immune evasion and immunotherapy resistance</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>7041</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-27349-7</pub-id><pub-id pub-id-type="pmid">34873175</pub-id><pub-id pub-id-type="pmcid">PMC8649069</pub-id></element-citation></ref><ref id="B14-pharmaceutics-14-02752"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>G.-Y.</given-names></name><name name-style="western"><surname>Farmer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>B.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.-M.</given-names></name><etal/></person-group><article-title>Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>1137</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-14821-z</pub-id><pub-id pub-id-type="pmid">32111835</pub-id><pub-id pub-id-type="pmcid">PMC7048819</pub-id></element-citation></ref><ref id="B15-pharmaceutics-14-02752"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maeda</surname><given-names>H.</given-names></name></person-group><article-title>Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity</article-title><source>Adv. Drug Deliver. Rev.</source><year>2015</year><volume>91</volume><fpage>3</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2015.01.002</pub-id><pub-id pub-id-type="pmid">25579058</pub-id></element-citation></ref><ref id="B16-pharmaceutics-14-02752"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Musetti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy</article-title><source>ACS Nano</source><year>2018</year><volume>12</volume><fpage>11740</fpage><lpage>11755</lpage><pub-id pub-id-type="doi">10.1021/acsnano.8b05893</pub-id><pub-id pub-id-type="pmid">30508378</pub-id></element-citation></ref><ref id="B17-pharmaceutics-14-02752"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y.-P.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>J.-R.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Z.-Y.</given-names></name></person-group><article-title>Advanced biomaterials for cancer immunotherapy</article-title><source>Acta Pharmacol. Sin.</source><year>2020</year><volume>41</volume><fpage>911</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1038/s41401-020-0372-z</pub-id><pub-id pub-id-type="pmid">32123302</pub-id><pub-id pub-id-type="pmcid">PMC7468530</pub-id></element-citation></ref><ref id="B18-pharmaceutics-14-02752"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Archer</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name></person-group><article-title>Innovations in lymph node targeting nanocarriers</article-title><source>Semin. Immunol.</source><year>2021</year><volume>56</volume><fpage>101534</fpage><pub-id pub-id-type="doi">10.1016/j.smim.2021.101534</pub-id><pub-id pub-id-type="pmid">34836772</pub-id><pub-id pub-id-type="pmcid">PMC8792237</pub-id></element-citation></ref><ref id="B19-pharmaceutics-14-02752"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schudel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Francis</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name></person-group><article-title>Material design for lymph node drug delivery</article-title><source>Nat. Rev. Mater.</source><year>2019</year><volume>4</volume><fpage>415</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1038/s41578-019-0110-7</pub-id><pub-id pub-id-type="pmid">32523780</pub-id><pub-id pub-id-type="pmcid">PMC7286627</pub-id></element-citation></ref><ref id="B20-pharmaceutics-14-02752"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manspeaker</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name></person-group><article-title>Lymphatic immunomodulation using engineered drug delivery systems for cancer immunotherapy</article-title><source>Adv. Drug Deliver. Rev.</source><year>2020</year><volume>160</volume><fpage>19</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.10.004</pub-id><pub-id pub-id-type="pmcid">PMC7736326</pub-id><pub-id pub-id-type="pmid">33058931</pub-id></element-citation></ref><ref id="B21-pharmaceutics-14-02752"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Rohner</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>E.E.</given-names></name></person-group><article-title>Implications of Lymphatic Transport to Lymph Nodes in Immunity and Immunotherapy</article-title><source>Annu. Rev. Biomed. Eng.</source><year>2016</year><volume>18</volume><fpage>207</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1146/annurev-bioeng-101515-014413</pub-id><pub-id pub-id-type="pmid">26928210</pub-id><pub-id pub-id-type="pmcid">PMC5518935</pub-id></element-citation></ref><ref id="B22-pharmaceutics-14-02752"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sestito</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name></person-group><article-title>Biomaterials for Modulating Lymphatic Function in Immunoengineering</article-title><source>ACS Pharmacol. Transl. Sci.</source><year>2019</year><volume>2</volume><fpage>293</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1021/acsptsci.9b00047</pub-id><pub-id pub-id-type="pmid">32259064</pub-id><pub-id pub-id-type="pmcid">PMC7088982</pub-id></element-citation></ref><ref id="B23-pharmaceutics-14-02752"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bagby</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>L.</given-names></name></person-group><article-title>Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles</article-title><source>Adv. Drug Deliver Rev.</source><year>2011</year><volume>63</volume><fpage>901</fpage><lpage>908</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2011.05.017</pub-id><pub-id pub-id-type="pmid">21712055</pub-id><pub-id pub-id-type="pmcid">PMC3164476</pub-id></element-citation></ref><ref id="B24-pharmaceutics-14-02752"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ravizzini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Turkbey</surname><given-names>B.</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Choyke</surname><given-names>P.L.</given-names></name></person-group><article-title>Nanoparticles in sentinel lymph node mapping</article-title><source>Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.</source><year>2009</year><volume>1</volume><fpage>610</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1002/wnan.48</pub-id><pub-id pub-id-type="pmid">20049820</pub-id><pub-id pub-id-type="pmcid">PMC6309687</pub-id></element-citation></ref><ref id="B25-pharmaceutics-14-02752"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Lymphatic Imaging: Focus on Imaging Probes</article-title><source>Theranostics</source><year>2015</year><volume>5</volume><fpage>686</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.7150/thno.11862</pub-id><pub-id pub-id-type="pmid">25897334</pub-id><pub-id pub-id-type="pmcid">PMC4402493</pub-id></element-citation></ref><ref id="B26-pharmaceutics-14-02752"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hameed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Irfan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bajwa</surname><given-names>S.Z.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Baig</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Z.</given-names></name></person-group><article-title>Fluorescence Guided Sentinel Lymph Node Mapping: From Current Molecular Probes to Future Multimodal Nanoprobes</article-title><source>Bioconjugate Chem.</source><year>2019</year><volume>30</volume><fpage>13</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.8b00812</pub-id><pub-id pub-id-type="pmid">30508381</pub-id></element-citation></ref><ref id="B27-pharmaceutics-14-02752"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name></person-group><article-title>Lymph node targeting strategies to improve vaccination efficacy</article-title><source>J. Control. Release</source><year>2017</year><volume>267</volume><fpage>47</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.08.009</pub-id><pub-id pub-id-type="pmid">28818619</pub-id></element-citation></ref><ref id="B28-pharmaceutics-14-02752"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trac</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>E.J.</given-names></name></person-group><article-title>Overcoming physiological barriers by nanoparticles for intravenous drug delivery to the lymph nodes</article-title><source>Exp. Biol. Med.</source><year>2021</year><volume>246</volume><fpage>2358</fpage><lpage>2371</lpage><pub-id pub-id-type="doi">10.1177/15353702211010762</pub-id><pub-id pub-id-type="pmcid">PMC8606962</pub-id><pub-id pub-id-type="pmid">33957802</pub-id></element-citation></ref><ref id="B29-pharmaceutics-14-02752"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gutjahr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Phelip</surname><given-names>C.</given-names></name><name name-style="western"><surname>Collen</surname><given-names>A.-L.</given-names></name><name name-style="western"><surname>Monge</surname><given-names>C.</given-names></name><name name-style="western"><surname>Boisgard</surname><given-names>A.-S.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Verrier</surname><given-names>B.</given-names></name></person-group><article-title>Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting</article-title><source>Vaccines</source><year>2016</year><volume>4</volume><elocation-id>34</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines4040034</pub-id><pub-id pub-id-type="pmid">27754314</pub-id><pub-id pub-id-type="pmcid">PMC5192354</pub-id></element-citation></ref><ref id="B30-pharmaceutics-14-02752"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahdev</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ochyl</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>J.J.</given-names></name></person-group><article-title>Biomaterials for Nanoparticle Vaccine Delivery Systems</article-title><source>Pharm. Res.</source><year>2014</year><volume>31</volume><fpage>2563</fpage><lpage>2582</lpage><pub-id pub-id-type="doi">10.1007/s11095-014-1419-y</pub-id><pub-id pub-id-type="pmid">24848341</pub-id><pub-id pub-id-type="pmcid">PMC4198431</pub-id></element-citation></ref><ref id="B31-pharmaceutics-14-02752"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Francis</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Manspeaker</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Schudel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sestito</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>O&#8217;Melia</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Kissick</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Pollack</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Waller</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name></person-group><article-title>Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy</article-title><source>Sci. Transl. Med.</source><year>2020</year><volume>12</volume><fpage>eaay3575</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aay3575</pub-id><pub-id pub-id-type="pmid">32998971</pub-id><pub-id pub-id-type="pmcid">PMC8377700</pub-id></element-citation></ref><ref id="B32-pharmaceutics-14-02752"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Quanyin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>He</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Injectable Bioresponsive Gel Depot for Enhanced Immune Checkpoint Blockade</article-title><source>Adv. Mater.</source><year>2018</year><volume>30</volume><fpage>1801527</fpage><pub-id pub-id-type="doi">10.1002/adma.201801527</pub-id><pub-id pub-id-type="pmid">29786888</pub-id></element-citation></ref><ref id="B33-pharmaceutics-14-02752"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z.</given-names></name></person-group><article-title>A Dual-Bioresponsive Drug-Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade</article-title><source>Adv. Mater.</source><year>2019</year><volume>31</volume><fpage>1806957</fpage><pub-id pub-id-type="doi">10.1002/adma.201806957</pub-id><pub-id pub-id-type="pmid">30856290</pub-id></element-citation></ref><ref id="B34-pharmaceutics-14-02752"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name></person-group><article-title>In Situ Formed Fibrin Scaffold with Cyclophosphamide to Synergize with Immune Checkpoint Blockade for Inhibition of Cancer Recurrence after Surgery</article-title><source>Adv. Funct. Mater.</source><year>2019</year><volume>30</volume><fpage>1906922</fpage><pub-id pub-id-type="doi">10.1002/adfm.201906922</pub-id></element-citation></ref><ref id="B35-pharmaceutics-14-02752"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Francis</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name></person-group><article-title>In Situ Crosslinked Hydrogel Depot for Sustained Antibody Release Improves Immune Checkpoint Blockade Cancer Immunotherapy</article-title><source>Nanomaterials</source><year>2021</year><volume>11</volume><elocation-id>471</elocation-id><pub-id pub-id-type="doi">10.3390/nano11020471</pub-id><pub-id pub-id-type="pmid">33673289</pub-id><pub-id pub-id-type="pmcid">PMC7918828</pub-id></element-citation></ref><ref id="B36-pharmaceutics-14-02752"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leach</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Young</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hartgerink</surname><given-names>J.D.</given-names></name></person-group><article-title>Advances in immunotherapy delivery from implantable and injectable biomaterials</article-title><source>Acta Biomater.</source><year>2019</year><volume>88</volume><fpage>15</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2019.02.016</pub-id><pub-id pub-id-type="pmid">30771535</pub-id><pub-id pub-id-type="pmcid">PMC6632081</pub-id></element-citation></ref><ref id="B37-pharmaceutics-14-02752"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Leong</surname><given-names>K.W.</given-names></name></person-group><article-title>Engineered biomaterials for cancer immunotherapy</article-title><source>MeComm</source><year>2020</year><volume>1</volume><fpage>35</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1002/mco2.8</pub-id><pub-id pub-id-type="pmcid">PMC8489675</pub-id><pub-id pub-id-type="pmid">34766108</pub-id></element-citation></ref><ref id="B38-pharmaceutics-14-02752"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.-H.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.</given-names></name></person-group><article-title>Injectable Hydrogel-Based Combination Cancer Immunotherapy for Overcoming Localized Therapeutic Efficacy</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>1908</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14091908</pub-id><pub-id pub-id-type="pmid">36145656</pub-id><pub-id pub-id-type="pmcid">PMC9502377</pub-id></element-citation></ref><ref id="B39-pharmaceutics-14-02752"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swartz</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Fleury</surname><given-names>M.E.</given-names></name></person-group><article-title>Interstitial Flow and Its Effects in Soft Tissues</article-title><source>Annu. Rev. Biomed. Eng.</source><year>2007</year><volume>9</volume><fpage>229</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1146/annurev.bioeng.9.060906.151850</pub-id><pub-id pub-id-type="pmid">17459001</pub-id></element-citation></ref><ref id="B40-pharmaceutics-14-02752"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rohner</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name></person-group><article-title>Flexible Macromolecule versus Rigid Particle Retention in the Injected Skin and Accumulation in Draining Lymph Nodes Are Differentially Influenced by Hydrodynamic Size</article-title><source>ACS Biomater. Sci. Eng.</source><year>2017</year><volume>3</volume><fpage>153</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1021/acsbiomaterials.6b00438</pub-id><pub-id pub-id-type="pmid">29888321</pub-id><pub-id pub-id-type="pmcid">PMC5990040</pub-id></element-citation></ref><ref id="B41-pharmaceutics-14-02752"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rohner</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name></person-group><article-title>Melanoma growth effects on molecular clearance from tumors and biodistribution into systemic tissues versus draining lymph nodes</article-title><source>J. Control. Release</source><year>2016</year><volume>223</volume><fpage>99</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2015.12.027</pub-id><pub-id pub-id-type="pmid">26721446</pub-id><pub-id pub-id-type="pmcid">PMC4724472</pub-id></element-citation></ref><ref id="B42-pharmaceutics-14-02752"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Melia</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Rohner</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Manspeaker</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Francis</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Kissick</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name></person-group><article-title>Quality of CD8<sup>+</sup> T cell immunity evoked in lymph nodes is compartmentalized by route of antigen transport and functional in tumor context</article-title><source>Sci. Adv.</source><year>2020</year><volume>6</volume><fpage>eabd7134</fpage><pub-id pub-id-type="doi">10.1126/sciadv.abd7134</pub-id><pub-id pub-id-type="pmid">33310857</pub-id><pub-id pub-id-type="pmcid">PMC7732197</pub-id></element-citation></ref><ref id="B43-pharmaceutics-14-02752"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reddy</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Berk</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Swartz</surname><given-names>M.A.</given-names></name></person-group><article-title>A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles</article-title><source>J. Appl. Physiol.</source><year>2006</year><volume>101</volume><fpage>1162</fpage><lpage>1169</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.00389.2006</pub-id><pub-id pub-id-type="pmid">16763103</pub-id></element-citation></ref><ref id="B44-pharmaceutics-14-02752"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Archer</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Sestito</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Manspeaker</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>O&#8217;Melia</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Rohner</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Schudel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name></person-group><article-title>Quantitation of lymphatic transport mechanism and barrier influences on lymph node-resident leukocyte access to lymph-borne macromolecules and drug delivery systems</article-title><source>Drug Deliv. Transl. Res.</source><year>2021</year><volume>11</volume><fpage>2328</fpage><lpage>2343</lpage><pub-id pub-id-type="doi">10.1007/s13346-021-01015-3</pub-id><pub-id pub-id-type="pmid">34165731</pub-id><pub-id pub-id-type="pmcid">PMC8571034</pub-id></element-citation></ref><ref id="B45-pharmaceutics-14-02752"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howard</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>X.</given-names></name><name name-style="western"><surname>Thayer</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Hamerly</surname><given-names>T.</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Dinglasan</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>H.-Q.</given-names></name></person-group><article-title>Critical size limit of biodegradable nanoparticles for enhanced lymph node trafficking and paracortex penetration</article-title><source>Nano Res.</source><year>2019</year><volume>12</volume><fpage>837</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1007/s12274-019-2301-3</pub-id><pub-id pub-id-type="pmid">33343832</pub-id><pub-id pub-id-type="pmcid">PMC7747954</pub-id></element-citation></ref><ref id="B46-pharmaceutics-14-02752"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.-N.</given-names></name><name name-style="western"><surname>Lazarovits</surname><given-names>J.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>L.N.M.</given-names></name><name name-style="western"><surname>Kingston</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>W.C.W.</given-names></name></person-group><article-title>Nanoparticle Size Influences Antigen Retention and Presentation in Lymph Node Follicles for Humoral Immunity</article-title><source>Nano Lett.</source><year>2019</year><volume>19</volume><fpage>7226</fpage><lpage>7235</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.9b02834</pub-id><pub-id pub-id-type="pmid">31508968</pub-id></element-citation></ref><ref id="B47-pharmaceutics-14-02752"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Maeki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tokeshi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Harashima</surname><given-names>H.</given-names></name></person-group><article-title>The Effect of Size and Charge of Lipid Nanoparticles Prepared by Microfluidic Mixing on Their Lymph Node Transitivity and Distribution</article-title><source>Mol. Pharm.</source><year>2020</year><volume>17</volume><fpage>944</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.9b01182</pub-id><pub-id pub-id-type="pmid">31990567</pub-id></element-citation></ref><ref id="B48-pharmaceutics-14-02752"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>M.</given-names></name></person-group><article-title>A surface charge dependent enhanced Th1 antigen-specific immune response in lymph nodes by transfersome-based nanovaccine-loaded dissolving microneedle-assisted transdermal immunization</article-title><source>J. Mater. Chem. B</source><year>2019</year><volume>7</volume><fpage>4854</fpage><lpage>4866</lpage><pub-id pub-id-type="doi">10.1039/C9TB00448C</pub-id><pub-id pub-id-type="pmid">31389952</pub-id></element-citation></ref><ref id="B49-pharmaceutics-14-02752"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baek</surname><given-names>J.-S.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>C.-W.</given-names></name></person-group><article-title>Surface modification of solid lipid nanoparticles for oral delivery of curcumin: Improvement of bioavailability through enhanced cellular uptake, and lymphatic uptake</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2017</year><volume>117</volume><fpage>132</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2017.04.013</pub-id><pub-id pub-id-type="pmid">28412471</pub-id></element-citation></ref><ref id="B50-pharmaceutics-14-02752"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishimoto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nagashima</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ohira</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>T.</given-names></name><name name-style="western"><surname>Izawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yamate</surname><given-names>J.</given-names></name><name name-style="western"><surname>Higashikawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kuge</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Carboxyl-, sulfonyl-, and phosphate-terminal dendrimers as a nanoplatform with lymph node targeting</article-title><source>Int. J. Pharm.</source><year>2020</year><volume>576</volume><fpage>119021</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2020.119021</pub-id><pub-id pub-id-type="pmid">31917298</pub-id></element-citation></ref><ref id="B51-pharmaceutics-14-02752"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knop</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hoogenboom</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schubert</surname><given-names>U.S.</given-names></name></person-group><article-title>Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives</article-title><source>Angew. Chem. Int. Ed.</source><year>2010</year><volume>49</volume><fpage>6288</fpage><lpage>6308</lpage><pub-id pub-id-type="doi">10.1002/anie.200902672</pub-id><pub-id pub-id-type="pmid">20648499</pub-id></element-citation></ref><ref id="B52-pharmaceutics-14-02752"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomasetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liebl</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wastl</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Breunig</surname><given-names>M.</given-names></name></person-group><article-title>Influence of PEGylation on nanoparticle mobility in different models of the extracellular matrix</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2016</year><volume>108</volume><fpage>145</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2016.08.007</pub-id><pub-id pub-id-type="pmid">27544052</pub-id></element-citation></ref><ref id="B53-pharmaceutics-14-02752"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mueller</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>S.</given-names></name><name name-style="western"><surname>DeSimone</surname><given-names>J.M.</given-names></name></person-group><article-title>Rapid and Persistent Delivery of Antigen by Lymph Node Targeting PRINT Nanoparticle Vaccine Carrier To Promote Humoral Immunity</article-title><source>Mol. Pharm.</source><year>2015</year><volume>12</volume><fpage>1356</fpage><lpage>1365</lpage><pub-id pub-id-type="doi">10.1021/mp500589c</pub-id><pub-id pub-id-type="pmid">25817072</pub-id><pub-id pub-id-type="pmcid">PMC4545241</pub-id></element-citation></ref><ref id="B54-pharmaceutics-14-02752"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zukancic</surname><given-names>D.</given-names></name><name name-style="western"><surname>Suys</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Pilkington</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Algarni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Wassiti</surname><given-names>H.</given-names></name><name name-style="western"><surname>Truong</surname><given-names>N.P.</given-names></name></person-group><article-title>The Importance of Poly(ethylene glycol) and Lipid Structure in Targeted Gene Delivery to Lymph Nodes by Lipid Nanoparticles</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>1068</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12111068</pub-id><pub-id pub-id-type="pmid">33182382</pub-id><pub-id pub-id-type="pmcid">PMC7695259</pub-id></element-citation></ref><ref id="B55-pharmaceutics-14-02752"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McCright</surname><given-names>J.</given-names></name><name name-style="western"><surname>Skeen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yarmovsky</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maisel</surname><given-names>K.</given-names></name></person-group><article-title>Nanoparticles with dense poly(ethylene glycol) coatings with near neutral charge are maximally transported across lymphatics and to the lymph nodes</article-title><source>Acta Biomater.</source><year>2022</year><volume>145</volume><fpage>146</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2022.03.054</pub-id><pub-id pub-id-type="pmid">35381399</pub-id><pub-id pub-id-type="pmcid">PMC9133124</pub-id></element-citation></ref><ref id="B56-pharmaceutics-14-02752"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shim</surname><given-names>G.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>Y.-K.</given-names></name></person-group><article-title>Lipid Nanoparticle-Mediated Lymphatic Delivery of Immunostimulatory Nucleic Acids</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>490</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13040490</pub-id><pub-id pub-id-type="pmid">33916667</pub-id><pub-id pub-id-type="pmcid">PMC8103501</pub-id></element-citation></ref><ref id="B57-pharmaceutics-14-02752"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uthaman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Revuri</surname><given-names>V.</given-names></name><name name-style="western"><surname>Min</surname><given-names>J.-J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.-K.</given-names></name><name name-style="western"><surname>Huh</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Park</surname><given-names>I.-K.</given-names></name></person-group><article-title>Green synthesis of bioactive polysaccharide-capped gold nanoparticles for lymph node CT imaging</article-title><source>Carbohydr. Polym.</source><year>2018</year><volume>181</volume><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2017.10.042</pub-id><pub-id pub-id-type="pmid">29253972</pub-id></element-citation></ref><ref id="B58-pharmaceutics-14-02752"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vu-Quang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>M.-K.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>H.-J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.-J.</given-names></name><name name-style="western"><surname>Muthiah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>C.-S.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>I.-K.</given-names></name></person-group><article-title>Targeted delivery of mannan-coated superparamagnetic iron oxide nanoparticles to antigen-presenting cells for magnetic resonance-based diagnosis of metastatic lymph nodes in vivo</article-title><source>Acta Biomater.</source><year>2011</year><volume>7</volume><fpage>3935</fpage><lpage>3945</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2011.06.044</pub-id><pub-id pub-id-type="pmid">21763797</pub-id></element-citation></ref><ref id="B59-pharmaceutics-14-02752"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vu-Quang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Muthiah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.-K.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>C.-S.</given-names></name><name name-style="western"><surname>Namgung</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Jun</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y.-J.</given-names></name><etal/></person-group><article-title>Carboxylic mannan-coated iron oxide nanoparticles targeted to immune cells for lymph node-specific MRI in vivo</article-title><source>Carbohydr. Polym.</source><year>2012</year><volume>88</volume><fpage>780</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2012.01.067</pub-id></element-citation></ref><ref id="B60-pharmaceutics-14-02752"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muthiah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vu-Quang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.-K.</given-names></name><name name-style="western"><surname>Rhee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Jun</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>C.-S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>I.-K.</given-names></name></person-group><article-title>Mannose-poly(ethylene glycol)-linked SPION targeted to antigen presenting cells for magnetic resonance imaging on lymph node</article-title><source>Carbohydr. Polym.</source><year>2013</year><volume>92</volume><fpage>1586</fpage><lpage>1595</lpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2012.11.011</pub-id><pub-id pub-id-type="pmid">23399193</pub-id></element-citation></ref><ref id="B61-pharmaceutics-14-02752"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Son</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zenkov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ochyl</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Scheetz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Farokhzad</surname><given-names>O.C.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>J.J.</given-names></name></person-group><article-title>Sugar-Nanocapsules Imprinted with Microbial Molecular Patterns for mRNA Vaccination</article-title><source>Nano Lett.</source><year>2020</year><volume>20</volume><fpage>1499</fpage><lpage>1509</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.9b03483</pub-id><pub-id pub-id-type="pmid">32023415</pub-id><pub-id pub-id-type="pmcid">PMC7286077</pub-id></element-citation></ref><ref id="B62-pharmaceutics-14-02752"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Song</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name></person-group><article-title>Nanoparticles with CD44 Targeting and ROS Triggering Properties as Effective in Vivo Antigen Delivery System</article-title><source>Mol. Pharm.</source><year>2018</year><volume>15</volume><fpage>508</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.7b00890</pub-id><pub-id pub-id-type="pmid">29323913</pub-id></element-citation></ref><ref id="B63-pharmaceutics-14-02752"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Heo</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>G.-S.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.-M.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>Y.T.</given-names></name></person-group><article-title>Multivalent Polymer Nanocomplex Targeting Endosomal Receptor of Immune Cells for Enhanced Antitumor and Systemic Memory Response</article-title><source>Angew. Chem.</source><year>2015</year><volume>127</volume><fpage>8257</fpage><lpage>8261</lpage><pub-id pub-id-type="doi">10.1002/ange.201501380</pub-id><pub-id pub-id-type="pmid">26014442</pub-id></element-citation></ref><ref id="B64-pharmaceutics-14-02752"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosalia</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>van Duikeren</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tromp</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W.</given-names></name><name name-style="western"><surname>de Gruijl</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lowik</surname><given-names>C.</given-names></name><name name-style="western"><surname>Oostendorp</surname><given-names>J.</given-names></name><name name-style="western"><surname>van der Burg</surname><given-names>S.H.</given-names></name><etal/></person-group><article-title>CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses</article-title><source>Biomaterials</source><year>2015</year><volume>40</volume><fpage>88</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.10.053</pub-id><pub-id pub-id-type="pmid">25465442</pub-id></element-citation></ref><ref id="B65-pharmaceutics-14-02752"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baekkevold</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Yamanaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Palframan</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Carlsen</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Reinholt</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>von Andrian</surname><given-names>U.H.</given-names></name><name name-style="western"><surname>Brandtzaeg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Haraldsen</surname><given-names>G.</given-names></name></person-group><article-title>The CCR7 Ligand ELC (CCL19) Is Transcytosed in High Endothelial Venules and Mediates T Cell Recruitment</article-title><source>J. Exp. Med.</source><year>2001</year><volume>193</volume><fpage>1105</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1084/jem.193.9.1105</pub-id><pub-id pub-id-type="pmid">11342595</pub-id><pub-id pub-id-type="pmcid">PMC2193428</pub-id></element-citation></ref><ref id="B66-pharmaceutics-14-02752"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palframan</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Weninger</surname><given-names>W.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dorf</surname><given-names>M.</given-names></name><name name-style="western"><surname>Littman</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Rollins</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Zweerink</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rot</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Inflammatory Chemokine Transport and Presentation in HEV: A Remote Control Mechanism for Monocyte Recruitment to Lymph Nodes in Inflamed Tissues</article-title><source>J. Exp. Med.</source><year>2001</year><volume>194</volume><fpage>1361</fpage><lpage>1373</lpage><pub-id pub-id-type="doi">10.1084/jem.194.9.1361</pub-id><pub-id pub-id-type="pmid">11696600</pub-id><pub-id pub-id-type="pmcid">PMC2195988</pub-id></element-citation></ref><ref id="B67-pharmaceutics-14-02752"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahmani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Uehara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ordikhani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Banouni</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ichimura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Solhjou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Furtmuller</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Brandacher</surname><given-names>G.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Targeted delivery of immune therapeutics to lymph nodes prolongs cardiac allograft survival</article-title><source>J. Clin. Investig.</source><year>2018</year><volume>128</volume><fpage>4770</fpage><lpage>4786</lpage><pub-id pub-id-type="doi">10.1172/JCI120923</pub-id><pub-id pub-id-type="pmid">30277476</pub-id><pub-id pub-id-type="pmcid">PMC6205374</pub-id></element-citation></ref><ref id="B68-pharmaceutics-14-02752"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ager</surname><given-names>A.</given-names></name></person-group><article-title>High endothelial venules and Other Blood vessels: Critical Regulators of Lymphoid Organ Development and Function</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>45</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.00045</pub-id><pub-id pub-id-type="pmid">28217126</pub-id><pub-id pub-id-type="pmcid">PMC5289948</pub-id></element-citation></ref><ref id="B69-pharmaceutics-14-02752"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoneyama</surname><given-names>H.</given-names></name><name name-style="western"><surname>Matsuno</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nishiwaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kitabatake</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ueha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Narumi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ezaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Evidence for recruitment of plasmacytoid dendritic cell precursors to inflamed lymph nodes through high endothelial venules</article-title><source>Int. Immunol.</source><year>2004</year><volume>16</volume><fpage>915</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxh093</pub-id><pub-id pub-id-type="pmid">15159375</pub-id></element-citation></ref><ref id="B70-pharmaceutics-14-02752"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kasinath</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ichimura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fiorina</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liss</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>K.</given-names></name><name name-style="western"><surname>Annabi</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Simultaneous targeting of primary tumor, draining lymph node, and distant metastases through high endothelial venule-targeted delivery</article-title><source>Nano Today</source><year>2021</year><volume>36</volume><fpage>101045</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2020.101045</pub-id><pub-id pub-id-type="pmid">33391389</pub-id><pub-id pub-id-type="pmcid">PMC7774643</pub-id></element-citation></ref><ref id="B71-pharmaceutics-14-02752"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azzi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Uehara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ohori</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ichimura</surname><given-names>T.</given-names></name><name name-style="western"><surname>McGrath</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maarouf</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kefaloyianni</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Targeted Delivery of Immunomodulators to Lymph Nodes</article-title><source>Cell Rep.</source><year>2016</year><volume>15</volume><fpage>1202</fpage><lpage>1213</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.04.007</pub-id><pub-id pub-id-type="pmid">27134176</pub-id><pub-id pub-id-type="pmcid">PMC4973867</pub-id></element-citation></ref><ref id="B72-pharmaceutics-14-02752"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahmani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Uehara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ordikhani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Banouni</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ichimura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kasinath</surname><given-names>V.</given-names></name><name name-style="western"><surname>Eskandari</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Annabi</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted delivery</article-title><source>EBioMedicine</source><year>2018</year><volume>38</volume><fpage>79</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2018.11.030</pub-id><pub-id pub-id-type="pmid">30497977</pub-id><pub-id pub-id-type="pmcid">PMC6306381</pub-id></element-citation></ref><ref id="B73-pharmaceutics-14-02752"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roozendaal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mempel</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Pitcher</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Verschoor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mebius</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>von Andrian</surname><given-names>U.H.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>M.C.</given-names></name></person-group><article-title>Conduits Mediate Transport of Low-Molecular-Weight Antigen to Lymph Node Follicles</article-title><source>Immunity</source><year>2009</year><volume>30</volume><fpage>264</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.12.014</pub-id><pub-id pub-id-type="pmid">19185517</pub-id><pub-id pub-id-type="pmcid">PMC2699624</pub-id></element-citation></ref><ref id="B74-pharmaceutics-14-02752"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Koker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vanparijs</surname><given-names>N.</given-names></name><name name-style="western"><surname>Albertazzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Grooten</surname><given-names>J.</given-names></name><name name-style="western"><surname>Caruso</surname><given-names>F.</given-names></name><name name-style="western"><surname>De Geest</surname><given-names>B.G.</given-names></name></person-group><article-title>Engineering Polymer Hydrogel Nanoparticles for Lymph Node-Targeted Delivery</article-title><source>Angew. Chem.</source><year>2016</year><volume>128</volume><fpage>1356</fpage><lpage>1361</lpage><pub-id pub-id-type="doi">10.1002/ange.201508626</pub-id><pub-id pub-id-type="pmid">26666207</pub-id></element-citation></ref><ref id="B75-pharmaceutics-14-02752"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klechevsky</surname><given-names>E.</given-names></name><name name-style="western"><surname>Morita</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Coquery</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thompson-Snipes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Briere</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chaussabel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zurawski</surname><given-names>G.</given-names></name><name name-style="western"><surname>Palucka</surname><given-names>A.K.</given-names></name><etal/></person-group><article-title>Functional Specializations of Human Epidermal Langerhans Cells and CD14<sup>+</sup> Dermal Dendritic Cells</article-title><source>Immunity</source><year>2008</year><volume>29</volume><fpage>497</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.07.013</pub-id><pub-id pub-id-type="pmid">18789730</pub-id><pub-id pub-id-type="pmcid">PMC2688399</pub-id></element-citation></ref><ref id="B76-pharmaceutics-14-02752"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandrasekaran</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>King</surname><given-names>M.R.</given-names></name></person-group><article-title>Super natural killer cells that target metastases in the tumor draining lymph nodes</article-title><source>Biomaterials</source><year>2016</year><volume>77</volume><fpage>66</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2015.11.001</pub-id><pub-id pub-id-type="pmid">26584347</pub-id><pub-id pub-id-type="pmcid">PMC4684422</pub-id></element-citation></ref><ref id="B77-pharmaceutics-14-02752"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmid</surname><given-names>D.</given-names></name><name name-style="western"><surname>Park</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Hartl</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Subedi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cartwright</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Bou Puerto</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Maiarana</surname><given-names>J.</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Wucherpfennig</surname><given-names>K.W.</given-names></name><etal/></person-group><article-title>T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>1747</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-01830-8</pub-id><pub-id pub-id-type="pmid">29170511</pub-id><pub-id pub-id-type="pmcid">PMC5700944</pub-id></element-citation></ref><ref id="B78-pharmaceutics-14-02752"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Longworthy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fine</surname><given-names>J.</given-names></name><etal/></person-group><article-title>PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy</article-title><source>Adv. Mater.</source><year>2018</year><volume>30</volume><fpage>1707112</fpage><pub-id pub-id-type="doi">10.1002/adma.201707112</pub-id><pub-id pub-id-type="pmid">29656492</pub-id></element-citation></ref><ref id="B79-pharmaceutics-14-02752"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kataoka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Harada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nagasaki</surname><given-names>Y.</given-names></name></person-group><article-title>Block copolymer micelles for drug delivery: Design, characterization and biological significance</article-title><source>Adv. Drug Deliver. Rev.</source><year>2012</year><volume>64</volume><fpage>37</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2012.09.013</pub-id><pub-id pub-id-type="pmid">11251249</pub-id></element-citation></ref><ref id="B80-pharmaceutics-14-02752"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Vokali</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lund</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Hubbell</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Swartz</surname><given-names>M.A.</given-names></name></person-group><article-title>Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response</article-title><source>Biomaterials</source><year>2014</year><volume>35</volume><fpage>814</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2013.10.003</pub-id><pub-id pub-id-type="pmid">24144906</pub-id></element-citation></ref><ref id="B81-pharmaceutics-14-02752"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sestito</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Im</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name></person-group><article-title>Poly(cyclodextrin)-Polydrug Nanocomplexes as Synthetic Oncolytic Virus for Locoregional Melanoma Chemoimmunotherapy</article-title><source>Adv. Funct. Mater.</source><year>2020</year><volume>30</volume><fpage>1908788</fpage><pub-id pub-id-type="doi">10.1002/adfm.201908788</pub-id><pub-id pub-id-type="pmid">33071710</pub-id><pub-id pub-id-type="pmcid">PMC7566879</pub-id></element-citation></ref><ref id="B82-pharmaceutics-14-02752"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horejs</surname><given-names>C.</given-names></name></person-group><article-title>From lipids to lipid nanoparticles to mRNA vaccines</article-title><source>Nat. Rev. Mater.</source><year>2021</year><volume>6</volume><fpage>1075</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.1038/s41578-021-00379-9</pub-id><pub-id pub-id-type="pmid">34567796</pub-id><pub-id pub-id-type="pmcid">PMC8454296</pub-id></element-citation></ref><ref id="B83-pharmaceutics-14-02752"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanson</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Crespo</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>W.</given-names></name><name name-style="western"><surname>Moynihan</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Szeto</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Melo</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Irvine</surname><given-names>D.J.</given-names></name></person-group><article-title>Nanoparticulate STING agonists are potent lymph node&#8211;targeted vaccine adjuvants</article-title><source>J. Clin. Investig.</source><year>2015</year><volume>125</volume><fpage>2532</fpage><lpage>2546</lpage><pub-id pub-id-type="doi">10.1172/JCI79915</pub-id><pub-id pub-id-type="pmid">25938786</pub-id><pub-id pub-id-type="pmcid">PMC4497758</pub-id></element-citation></ref><ref id="B84-pharmaceutics-14-02752"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oberli</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Reichmuth</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Dorkin</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Fenton</surname><given-names>O.S.</given-names></name><name name-style="western"><surname>Jaklenec</surname><given-names>A.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Blankschtein</surname><given-names>D.</given-names></name></person-group><article-title>Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy</article-title><source>Nano Lett.</source><year>2017</year><volume>17</volume><fpage>1326</fpage><lpage>1335</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.6b03329</pub-id><pub-id pub-id-type="pmid">28273716</pub-id><pub-id pub-id-type="pmcid">PMC5523404</pub-id></element-citation></ref><ref id="B85-pharmaceutics-14-02752"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bourquin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Anz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zwiorek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lanz</surname><given-names>A.-L.</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wigel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wurzenberger</surname><given-names>C.</given-names></name><name name-style="western"><surname>von der Borch</surname><given-names>P.</given-names></name><name name-style="western"><surname>Golic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moder</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Targeting CpG Oligonucleotides to the Lymph Node by Nanoparticles Elicits Efficient Antitumoral Immunity</article-title><source>J. Immunol.</source><year>2008</year><volume>181</volume><fpage>2990</fpage><lpage>2998</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.5.2990</pub-id><pub-id pub-id-type="pmid">18713969</pub-id></element-citation></ref><ref id="B86-pharmaceutics-14-02752"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name></person-group><article-title>Tailoring polymeric hybrid micelles with lymph node targeting ability to improve the potency of cancer vaccines</article-title><source>Biomaterials</source><year>2017</year><volume>122</volume><fpage>105</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2017.01.010</pub-id><pub-id pub-id-type="pmid">28110170</pub-id></element-citation></ref><ref id="B87-pharmaceutics-14-02752"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Noh</surname><given-names>Y.-W.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.-E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Um</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>D.-B.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.-M.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>Y.T.</given-names></name></person-group><article-title>Synthetic vaccine nanoparticles target to lymph node triggering enhanced innate and adaptive antitumor immunity</article-title><source>Biomaterials</source><year>2017</year><volume>130</volume><fpage>56</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2017.03.034</pub-id><pub-id pub-id-type="pmid">28364631</pub-id></element-citation></ref><ref id="B88-pharmaceutics-14-02752"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name></person-group><article-title>Silica Nanoparticle as a Lymph Node Targeting Platform for Vaccine Delivery</article-title><source>ACS Appl. Mater. Interfaces</source><year>2017</year><volume>9</volume><fpage>23466</fpage><lpage>23475</lpage><pub-id pub-id-type="doi">10.1021/acsami.7b06024</pub-id><pub-id pub-id-type="pmid">28640587</pub-id></element-citation></ref><ref id="B89-pharmaceutics-14-02752"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C.</given-names></name></person-group><article-title>Glutathione-depletion mesoporous organosilica nanoparticles as a self-adjuvant and Co-delivery platform for enhanced cancer immunotherapy</article-title><source>Biomaterials</source><year>2018</year><volume>175</volume><fpage>82</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.05.025</pub-id><pub-id pub-id-type="pmid">29803106</pub-id></element-citation></ref><ref id="B90-pharmaceutics-14-02752"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name></person-group><article-title>Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8<sup>+</sup> T Cell Responses</article-title><source>Adv. Sci.</source><year>2018</year><volume>5</volume><fpage>1700426</fpage><pub-id pub-id-type="doi">10.1002/advs.201700426</pub-id><pub-id pub-id-type="pmcid">PMC5770685</pub-id><pub-id pub-id-type="pmid">29375970</pub-id></element-citation></ref><ref id="B91-pharmaceutics-14-02752"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mody</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Popat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mahony</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cavallaro</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mitter</surname><given-names>N.</given-names></name></person-group><article-title>Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine delivery</article-title><source>Nanoscale</source><year>2013</year><volume>5</volume><fpage>5167</fpage><lpage>5179</lpage><pub-id pub-id-type="doi">10.1039/c3nr00357d</pub-id><pub-id pub-id-type="pmid">23657437</pub-id></element-citation></ref><ref id="B92-pharmaceutics-14-02752"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mok</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Park</surname><given-names>T.G.</given-names></name></person-group><article-title>Multimeric small interfering ribonucleic acid for highly efficient sequence-specific gene silencing</article-title><source>Nat. Mater.</source><year>2010</year><volume>9</volume><fpage>272</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1038/nmat2626</pub-id><pub-id pub-id-type="pmid">20098433</pub-id></element-citation></ref><ref id="B93-pharmaceutics-14-02752"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vishwasrao</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>O.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yung</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>1482</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-01386-7</pub-id><pub-id pub-id-type="pmid">29133898</pub-id><pub-id pub-id-type="pmcid">PMC5684198</pub-id></element-citation></ref><ref id="B94-pharmaceutics-14-02752"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ni</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Su</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><etal/></person-group><article-title>A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer</article-title><source>Sci. Adv.</source><year>2020</year><volume>6</volume><fpage>eaaw6071</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aaw6071</pub-id><pub-id pub-id-type="pmid">32206706</pub-id><pub-id pub-id-type="pmcid">PMC7080439</pub-id></element-citation></ref><ref id="B95-pharmaceutics-14-02752"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name></person-group><article-title>Nucleic Acid Nanostructure Assisted Immune Modulation</article-title><source>ACS Appl. Bio Mater.</source><year>2020</year><volume>3</volume><fpage>2765</fpage><lpage>2778</lpage><pub-id pub-id-type="doi">10.1021/acsabm.9b01195</pub-id><pub-id pub-id-type="pmid">35025407</pub-id></element-citation></ref><ref id="B96-pharmaceutics-14-02752"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cutler</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Auyeung</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mirkin</surname><given-names>C.A.</given-names></name></person-group><article-title>Spherical Nucleic Acids</article-title><source>J. Am. Chem. Soc.</source><year>2012</year><volume>134</volume><fpage>1376</fpage><lpage>1391</lpage><pub-id pub-id-type="doi">10.1021/ja209351u</pub-id><pub-id pub-id-type="pmid">22229439</pub-id></element-citation></ref><ref id="B97-pharmaceutics-14-02752"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radovic-Moreno</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Chernyak</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mader</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Nallagatla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Halo</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Merkel</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Rische</surname><given-names>C.H.</given-names></name><etal/></person-group><article-title>Immunomodulatory spherical nucleic acids</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2015</year><volume>112</volume><fpage>3892</fpage><lpage>3897</lpage><pub-id pub-id-type="doi">10.1073/pnas.1502850112</pub-id><pub-id pub-id-type="pmid">25775582</pub-id><pub-id pub-id-type="pmcid">PMC4386353</pub-id></element-citation></ref><ref id="B98-pharmaceutics-14-02752"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Callmann</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Kusmeierz</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Dittmar</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Broger</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mirkin</surname><given-names>C.A.</given-names></name></person-group><article-title>Impact of Liposomal Spherical Nucleic Acid Structure on Immunotherapeutic Function</article-title><source>ACS Cent. Sci.</source><year>2021</year><volume>7</volume><fpage>892</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1021/acscentsci.1c00181</pub-id><pub-id pub-id-type="pmid">34079904</pub-id><pub-id pub-id-type="pmcid">PMC8161491</pub-id></element-citation></ref><ref id="B99-pharmaceutics-14-02752"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ochyl</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Bahjat</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Schwendeman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>J.J.</given-names></name></person-group><article-title>Designer vaccine nanodiscs for personalized cancer immunotherapy</article-title><source>Nat. Mater.</source><year>2017</year><volume>16</volume><fpage>489</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1038/nmat4822</pub-id><pub-id pub-id-type="pmid">28024156</pub-id><pub-id pub-id-type="pmcid">PMC5374005</pub-id></element-citation></ref><ref id="B100-pharmaceutics-14-02752"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Callmann</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Kusmierz</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Horiuchi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mirkin</surname><given-names>C.A.</given-names></name></person-group><article-title>Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>17543</fpage><lpage>17550</lpage><pub-id pub-id-type="doi">10.1073/pnas.2005794117</pub-id><pub-id pub-id-type="pmid">32669433</pub-id><pub-id pub-id-type="pmcid">PMC7395518</pub-id></element-citation></ref><ref id="B101-pharmaceutics-14-02752"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Maximizing TLR9 Activation in Cancer Immunotherapy with DualAdjuvanted Spherical Nucleic Acids</article-title><source>Nano Lett.</source><year>2022</year><volume>22</volume><fpage>4058</fpage><lpage>4066</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.2c00723</pub-id><pub-id pub-id-type="pmid">35522597</pub-id><pub-id pub-id-type="pmcid">PMC9164000</pub-id></element-citation></ref><ref id="B102-pharmaceutics-14-02752"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>Y.</given-names></name></person-group><article-title>The Beauty and Utility of DNA Origami</article-title><source>Chem</source><year>2017</year><volume>2</volume><fpage>359</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/j.chempr.2017.02.009</pub-id></element-citation></ref><ref id="B103-pharmaceutics-14-02752"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>K.-R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.-D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>B.-S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>D.-R.</given-names></name></person-group><article-title>Sentinel lymph node imaging by a fluorescently labeled DNA tetrahedron</article-title><source>Biomaterials</source><year>2013</year><volume>34</volume><fpage>5226</fpage><lpage>5235</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2013.03.074</pub-id><pub-id pub-id-type="pmid">23587443</pub-id></element-citation></ref><ref id="B104-pharmaceutics-14-02752"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.</given-names></name><etal/></person-group><article-title>A DNA nanodevice-based vaccine for cancer immunotherapy</article-title><source>Nat. Mater.</source><year>2021</year><volume>20</volume><fpage>421</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1038/s41563-020-0793-6</pub-id><pub-id pub-id-type="pmid">32895504</pub-id></element-citation></ref><ref id="B105-pharmaceutics-14-02752"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>G.</given-names></name></person-group><article-title>Lymph Node-Targeting Nanovaccine through Antigen-CpG Self-Assembly Potentiates Cytotoxic T Cell Activation</article-title><source>J. Immunol. Res.</source><year>2018</year><volume>2018</volume><fpage>3714960</fpage><pub-id pub-id-type="doi">10.1155/2018/3714960</pub-id><pub-id pub-id-type="pmid">30018987</pub-id><pub-id pub-id-type="pmcid">PMC6029500</pub-id></element-citation></ref><ref id="B106-pharmaceutics-14-02752"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>Nanoscale Coordination Polymer Based Nanovaccine for Tumor Immunotherapy</article-title><source>ACS Nano</source><year>2019</year><volume>13</volume><fpage>13127</fpage><lpage>13135</lpage><pub-id pub-id-type="doi">10.1021/acsnano.9b05974</pub-id><pub-id pub-id-type="pmid">31710460</pub-id></element-citation></ref><ref id="B107-pharmaceutics-14-02752"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>B.-R.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Na</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Byun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>I.C.</given-names></name><etal/></person-group><article-title>Engineered Human Ferritin Nanoparticles for Direct Delivery of Tumor Antigens to Lymph Node and Cancer Immunotherapy</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>35182</fpage><pub-id pub-id-type="doi">10.1038/srep35182</pub-id><pub-id pub-id-type="pmid">27725782</pub-id><pub-id pub-id-type="pmcid">PMC5057094</pub-id></element-citation></ref><ref id="B108-pharmaceutics-14-02752"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>H.-D.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>G.-H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>I.-S.</given-names></name></person-group><article-title>Design of PD-1-decorated nanocages targeting tumor-draining lymph node for promoting T cell activation</article-title><source>J. Control. Release</source><year>2021</year><volume>333</volume><fpage>328</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2021.03.038</pub-id><pub-id pub-id-type="pmid">33794271</pub-id></element-citation></ref><ref id="B109-pharmaceutics-14-02752"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Noh</surname><given-names>Y.-W.</given-names></name><name name-style="western"><surname>Heo</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>Y.T.</given-names></name></person-group><article-title>Multifunctional Hybrid Nanoconjugates for Efficient In Vivo Delivery of Immunomodulating Oligonucleotides and Enhanced Antitumor Immunity</article-title><source>Angew. Chem. Int. Ed.</source><year>2012</year><volume>51</volume><fpage>9670</fpage><lpage>9673</lpage><pub-id pub-id-type="doi">10.1002/anie.201204989</pub-id><pub-id pub-id-type="pmid">22915476</pub-id></element-citation></ref><ref id="B110-pharmaceutics-14-02752"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruiz-de-Angulo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zabaleta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gomez-Vallejo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Llop</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mareque-Rivas</surname><given-names>J.C.</given-names></name></person-group><article-title>Microdosed Lipid-Coated 67 Ga-Magnetite Enhances Antigen-Specific Immunity by Image Tracked Delivery of Antigen and CpG to Lymph Nodes</article-title><source>ACS Nano</source><year>2016</year><volume>10</volume><fpage>1602</fpage><lpage>1618</lpage><pub-id pub-id-type="doi">10.1021/acsnano.5b07253</pub-id><pub-id pub-id-type="pmid">26678549</pub-id></element-citation></ref><ref id="B111-pharmaceutics-14-02752"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Aikins</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>J.J.</given-names></name></person-group><article-title>Efficient Lymph Node-Targeted Delivery of Personalized Cancer Vaccines with Reactive Oxygen Species-Inducing Reduced Graphene Oxide Nanosheets</article-title><source>ACS Nano</source><year>2020</year><volume>14</volume><fpage>13268</fpage><lpage>13278</lpage><pub-id pub-id-type="doi">10.1021/acsnano.0c05062</pub-id><pub-id pub-id-type="pmid">32902245</pub-id><pub-id pub-id-type="pmcid">PMC7606610</pub-id></element-citation></ref><ref id="B112-pharmaceutics-14-02752"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma</article-title><source>J. Nanobiotechnology</source><year>2022</year><volume>20</volume><fpage>190</fpage><pub-id pub-id-type="doi">10.1186/s12951-022-01397-7</pub-id><pub-id pub-id-type="pmid">35418151</pub-id><pub-id pub-id-type="pmcid">PMC9006542</pub-id></element-citation></ref><ref id="B113-pharmaceutics-14-02752"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name></person-group><article-title>Lymph Node Delivery Strategy Enables the Activation of Cytotoxic T Lymphocytes and Natural Killer Cells to Augment Cancer Immunotherapy</article-title><source>ACS Appl. Mater. Interfaces</source><year>2021</year><volume>13</volume><fpage>22213</fpage><lpage>22224</lpage><pub-id pub-id-type="doi">10.1021/acsami.1c03709</pub-id><pub-id pub-id-type="pmid">33955746</pub-id></element-citation></ref><ref id="B114-pharmaceutics-14-02752"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>G.-N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.-N.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>J.-F.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H.-J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.-Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.-W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.-M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.-Q.</given-names></name><etal/></person-group><article-title>Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine</article-title><source>Biomaterials</source><year>2017</year><volume>113</volume><fpage>191</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2016.10.047</pub-id><pub-id pub-id-type="pmid">27816821</pub-id></element-citation></ref><ref id="B115-pharmaceutics-14-02752"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>F.</given-names></name></person-group><article-title>Tumor-draining lymph node targeting chitosan micelles as antigen-capturing adjuvants for personalized immunotherapy</article-title><source>Carbohydr. Polym.</source><year>2020</year><volume>240</volume><fpage>116270</fpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2020.116270</pub-id><pub-id pub-id-type="pmid">32475559</pub-id></element-citation></ref><ref id="B116-pharmaceutics-14-02752"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Targeted antigen delivery to dendritic cell via functionalized alginate nanoparticles for cancer immunotherapy</article-title><source>J. Control. Release</source><year>2017</year><volume>256</volume><fpage>170</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.04.020</pub-id><pub-id pub-id-type="pmid">28414151</pub-id></element-citation></ref><ref id="B117-pharmaceutics-14-02752"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peeler</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Olshefsky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sylvestre</surname><given-names>M.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stayton</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Pun</surname><given-names>S.H.</given-names></name></person-group><article-title>Well-Defined Mannosylated Polymer for Peptide Vaccine Delivery with Enhanced Antitumor Immunity</article-title><source>Adv. Healthc. Mater.</source><year>2022</year><volume>11</volume><fpage>2101651</fpage><pub-id pub-id-type="doi">10.1002/adhm.202101651</pub-id><pub-id pub-id-type="pmcid">PMC9043035</pub-id><pub-id pub-id-type="pmid">34706166</pub-id></element-citation></ref><ref id="B118-pharmaceutics-14-02752"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>K.</given-names></name></person-group><article-title>Improving Cancer Immunotherapy by Cell Membrane-Camouflaged Nanoparticles</article-title><source>Adv. Funct. Mater.</source><year>2020</year><volume>30</volume><fpage>2004397</fpage><pub-id pub-id-type="doi">10.1002/adfm.202004397</pub-id></element-citation></ref><ref id="B119-pharmaceutics-14-02752"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name></person-group><article-title>Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma</article-title><source>ACS Nano</source><year>2015</year><volume>9</volume><fpage>6918</fpage><lpage>6933</lpage><pub-id pub-id-type="doi">10.1021/acsnano.5b01042</pub-id><pub-id pub-id-type="pmid">26153897</pub-id></element-citation></ref><ref id="B120-pharmaceutics-14-02752"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination</article-title><source>ACS Nano</source><year>2018</year><volume>12</volume><fpage>5121</fpage><lpage>5129</lpage><pub-id pub-id-type="doi">10.1021/acsnano.7b09041</pub-id><pub-id pub-id-type="pmid">29771487</pub-id></element-citation></ref><ref id="B121-pharmaceutics-14-02752"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>F.</given-names></name></person-group><article-title>pH-Responsive Biomimetic Polymeric Micelles as Lymph NodeTargeting Vaccines for Enhanced Antitumor Immune Responses</article-title><source>Biomacromolecules</source><year>2020</year><volume>21</volume><fpage>2818</fpage><lpage>2828</lpage><pub-id pub-id-type="doi">10.1021/acs.biomac.0c00518</pub-id><pub-id pub-id-type="pmid">32496052</pub-id></element-citation></ref><ref id="B122-pharmaceutics-14-02752"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Engineering Nanoscale Artificial Antigen-Presenting Cells by Metabolic Dendritic Cell Labeling to Potentiate Cancer Immunotherapy</article-title><source>Nano Lett.</source><year>2021</year><volume>21</volume><fpage>2094</fpage><lpage>2103</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.0c04783</pub-id><pub-id pub-id-type="pmid">33622034</pub-id></element-citation></ref><ref id="B123-pharmaceutics-14-02752"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>W.-L.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>M.-Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>W.-Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.-X.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.-J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>W.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Cytomembrane nanovaccines show therapeutic effects by mimicking tumor cells and antigen presenting cells</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>3199</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-11157-1</pub-id><pub-id pub-id-type="pmid">31324770</pub-id><pub-id pub-id-type="pmcid">PMC6642123</pub-id></element-citation></ref><ref id="B124-pharmaceutics-14-02752"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sheu</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Copresentation of Tumor Antigens and Costimulatory Molecules via Biomimetic Nanoparticles for Effective Cancer Immunotherapy</article-title><source>Nano Lett.</source><year>2020</year><volume>20</volume><fpage>4084</fpage><lpage>4094</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.9b05171</pub-id><pub-id pub-id-type="pmid">32379462</pub-id></element-citation></ref><ref id="B125-pharmaceutics-14-02752"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herrmann</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>M.J.A.</given-names></name><name name-style="western"><surname>Fuhrmann</surname><given-names>G.</given-names></name></person-group><article-title>Extracellular vesicles as a next-generation drug delivery platform</article-title><source>Nat. Nanotech.</source><year>2021</year><volume>16</volume><fpage>748</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1038/s41565-021-00931-2</pub-id><pub-id pub-id-type="pmid">34211166</pub-id></element-citation></ref><ref id="B126-pharmaceutics-14-02752"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phung</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>H.-G.</given-names></name><name name-style="western"><surname>Ku</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Yong</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.O.</given-names></name></person-group><article-title>Anti-CTLA-4 antibody-functionalized dendritic cell-derived exosomes targeting tumor-draining lymph nodes for effective induction of antitumor T-cell responses</article-title><source>Acta Biomater.</source><year>2020</year><volume>115</volume><fpage>371</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2020.08.008</pub-id><pub-id pub-id-type="pmid">32798721</pub-id></element-citation></ref><ref id="B127-pharmaceutics-14-02752"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>Exosomes from M1-Polarized Macrophages Potentiate the Cancer Vaccine by Creating a Proinflammatory Microenvironment in the Lymph Node</article-title><source>Mol. Ther.</source><year>2017</year><volume>25</volume><fpage>1665</fpage><lpage>1675</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.02.007</pub-id><pub-id pub-id-type="pmid">28284981</pub-id><pub-id pub-id-type="pmcid">PMC5498801</pub-id></element-citation></ref><ref id="B128-pharmaceutics-14-02752"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schudel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Yau</surname><given-names>M.-K.</given-names></name><name name-style="western"><surname>Higginson</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Francis</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Manspeaker</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Avecilla</surname><given-names>A.R.C.</given-names></name><name name-style="western"><surname>Rohner</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Finn</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name></person-group><article-title>Programmable multistage drug delivery to lymph nodes</article-title><source>Nat. Nanotech.</source><year>2020</year><volume>15</volume><fpage>491</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1038/s41565-020-0679-4</pub-id><pub-id pub-id-type="pmcid">PMC7305972</pub-id><pub-id pub-id-type="pmid">32523099</pub-id></element-citation></ref><ref id="B129-pharmaceutics-14-02752"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Trojan Horse nanotheranostics with dual transformability and multifunctionality for highly effective cancer treatment</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>3653</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-06093-5</pub-id><pub-id pub-id-type="pmid">30194413</pub-id><pub-id pub-id-type="pmcid">PMC6128896</pub-id></element-citation></ref><ref id="B130-pharmaceutics-14-02752"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.-J.</given-names></name><name name-style="western"><surname>Du</surname><given-names>J.-Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Du</surname><given-names>X.-J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>X.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>Smart Superstructures with Ultrahigh pHSensitivity for Targeting Acidic Tumor Microenvironment: Instantaneous Size Switching and Improved Tumor Penetration</article-title><source>ACS Nano</source><year>2016</year><volume>10</volume><fpage>6753</fpage><lpage>6761</lpage><pub-id pub-id-type="doi">10.1021/acsnano.6b02326</pub-id><pub-id pub-id-type="pmid">27244096</pub-id></element-citation></ref><ref id="B131-pharmaceutics-14-02752"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>W.</given-names></name><name name-style="western"><surname>He</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name></person-group><article-title>Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment</article-title><source>Theranostics</source><year>2017</year><volume>7</volume><fpage>538</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.7150/thno.16684</pub-id><pub-id pub-id-type="pmid">28255348</pub-id><pub-id pub-id-type="pmcid">PMC5327631</pub-id></element-citation></ref><ref id="B132-pharmaceutics-14-02752"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huynh</surname><given-names>V.</given-names></name><name name-style="western"><surname>Jesmer</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Shoaib</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>D&#8217;Angelo</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Rullo</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Wylie</surname><given-names>R.G.</given-names></name></person-group><article-title>Improved Efficacy of Antibody Cancer Immunotherapeutics through Local and Sustained Delivery</article-title><source>ChemBioChem</source><year>2019</year><volume>20</volume><fpage>747</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1002/cbic.201800579</pub-id><pub-id pub-id-type="pmid">30426647</pub-id></element-citation></ref><ref id="B133-pharmaceutics-14-02752"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lovell</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Secretions from hypochlorous acid-treated tumor cells delivered in a melittin hydrogel potentiate cancer immunotherapy</article-title><source>Bioact. Mater.</source><year>2022</year><volume>9</volume><fpage>541</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1016/j.bioactmat.2021.07.019</pub-id><pub-id pub-id-type="pmid">34820587</pub-id><pub-id pub-id-type="pmcid">PMC8591392</pub-id></element-citation></ref><ref id="B134-pharmaceutics-14-02752"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.K.</given-names></name></person-group><article-title>A general strategy towards an injectable microwave-sensitive immune hydrogel for combined percutaneous microwave ablation and immunotherapy</article-title><source>Chem. Eng. J.</source><year>2021</year><volume>422</volume><fpage>130111</fpage><pub-id pub-id-type="doi">10.1016/j.cej.2021.130111</pub-id></element-citation></ref><ref id="B135-pharmaceutics-14-02752"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dahiru</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>A bio-responsive, cargo-catchable gel for postsurgical tumor treatment via ICD-based immunotherapy</article-title><source>J. Control. Release</source><year>2022</year><volume>346</volume><fpage>212</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.04.015</pub-id><pub-id pub-id-type="pmid">35461965</pub-id></element-citation></ref><ref id="B136-pharmaceutics-14-02752"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.-P.</given-names></name><etal/></person-group><article-title>Tumor Ablation and Therapeutic Immunity Induction by an Injectable Peptide Hydrogel</article-title><source>ACS Nano</source><year>2018</year><volume>12</volume><fpage>3295</fpage><lpage>3310</lpage><pub-id pub-id-type="doi">10.1021/acsnano.7b08148</pub-id><pub-id pub-id-type="pmid">29558107</pub-id></element-citation></ref><ref id="B137-pharmaceutics-14-02752"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Z.</given-names></name></person-group><article-title>Cyclophosphamide loaded thermo-responsive hydrogel system synergize with a hydrogel cancer vaccine to amplify cancer immunotherapy in a prime-boost manner</article-title><source>Bioact. Mater.</source><year>2021</year><volume>6</volume><fpage>3036</fpage><lpage>3048</lpage><pub-id pub-id-type="doi">10.1016/j.bioactmat.2021.03.003</pub-id><pub-id pub-id-type="pmid">33778186</pub-id><pub-id pub-id-type="pmcid">PMC7960683</pub-id></element-citation></ref><ref id="B138-pharmaceutics-14-02752"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Le</surname><given-names>Q.-V.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>Y.-K.</given-names></name></person-group><article-title>Improved Efficacy of Antibody Cancer Immunotherapeutics through Local and Sustained Delivery</article-title><source>Biomaterials</source><year>2019</year><volume>218</volume><fpage>119359</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2019.119359</pub-id><pub-id pub-id-type="pmid">30426647</pub-id></element-citation></ref><ref id="B139-pharmaceutics-14-02752"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fei</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Bioadhesive injectable hydrogel with phenolic carbon quantum dot supported Pd single atom nanozymes as a localized immunomodulation niche for cancer catalytic immunotherapy</article-title><source>Biomaterials</source><year>2022</year><volume>280</volume><fpage>121272</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2021.121272</pub-id><pub-id pub-id-type="pmid">34864428</pub-id></element-citation></ref><ref id="B140-pharmaceutics-14-02752"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X.-j.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name></person-group><article-title>Biomineralized hydrogel DC vaccine for cancer immunotherapy: A boosting strategy via improving immunogenicity and reversing immune-inhibitory microenvironment</article-title><source>Biomaterials</source><year>2022</year><volume>288</volume><fpage>121722</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2022.121722</pub-id><pub-id pub-id-type="pmid">35963815</pub-id></element-citation></ref><ref id="B141-pharmaceutics-14-02752"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L.</given-names></name><name name-style="western"><surname>He</surname><given-names>W.</given-names></name><name name-style="western"><surname>Teng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>H.</given-names></name><etal/></person-group><article-title>In situ targeting nanoparticles-hydrogel hybrid system for combined chemo-immunotherapy of glioma</article-title><source>J. Control. Release</source><year>2022</year><volume>345</volume><fpage>786</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.03.050</pub-id><pub-id pub-id-type="pmid">35367277</pub-id></element-citation></ref><ref id="B142-pharmaceutics-14-02752"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Luan</surname><given-names>Y.</given-names></name></person-group><article-title>An injectable hydrogel using an immunomodulating gelator for amplified tumor immunotherapy by blocking the arginase pathway</article-title><source>Acta Biomater.</source><year>2021</year><volume>124</volume><fpage>179</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2021.01.041</pub-id><pub-id pub-id-type="pmid">33524560</pub-id></element-citation></ref><ref id="B143-pharmaceutics-14-02752"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy</article-title><source>Acta Biomater.</source><year>2022</year><volume>149</volume><fpage>334</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2022.06.041</pub-id><pub-id pub-id-type="pmid">35779775</pub-id></element-citation></ref><ref id="B144-pharmaceutics-14-02752"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zi</surname><given-names>H.</given-names></name><name name-style="western"><surname>He</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lovell</surname><given-names>J.F.</given-names></name><etal/></person-group><article-title>Peptide hydrogels loaded with irradiated tumor cell secretions enhance cancer immunotherapy</article-title><source>Nano Today</source><year>2021</year><volume>41</volume><fpage>101323</fpage><pub-id pub-id-type="doi">10.1016/j.nantod.2021.101323</pub-id></element-citation></ref><ref id="B145-pharmaceutics-14-02752"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.-R.</given-names></name><etal/></person-group><article-title>PEIGel: A biocompatible and injectable scaffold with innate immune adjuvanticity for synergized local immunotherapy</article-title><source>Mater. Today Bio</source><year>2022</year><volume>15</volume><fpage>100297</fpage><pub-id pub-id-type="doi">10.1016/j.mtbio.2022.100297</pub-id><pub-id pub-id-type="pmcid">PMC9142629</pub-id><pub-id pub-id-type="pmid">35637855</pub-id></element-citation></ref><ref id="B146-pharmaceutics-14-02752"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name></person-group><article-title>Inosine-Based Supramolecular Hydrogel for Highly Efficient PD-L1 Blockade Therapy via Mediating CD8<sup>+</sup> T Cells</article-title><source>Adv. Funct. Mater.</source><year>2022</year><volume>32</volume><fpage>2204273</fpage><pub-id pub-id-type="doi">10.1002/adfm.202204273</pub-id></element-citation></ref><ref id="B147-pharmaceutics-14-02752"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Immunostimulant In Situ Hydrogel Improves Synergetic Radioimmunotherapy of Malignant Glioblastoma Relapse Post-Resection</article-title><source>Adv. Funct. Mater.</source><year>2022</year><volume>32</volume><fpage>2205038</fpage><pub-id pub-id-type="doi">10.1002/adfm.202205038</pub-id></element-citation></ref><ref id="B148-pharmaceutics-14-02752"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Si</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Song</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>In&#8211;Situ-Sprayed Dual-Functional Immunotherapeutic Gel for Colorectal Cancer Postsurgical Treatment</article-title><source>Adv. Healthc. Mater.</source><year>2021</year><volume>10</volume><fpage>2100862</fpage><pub-id pub-id-type="doi">10.1002/adhm.202100862</pub-id><pub-id pub-id-type="pmid">34347370</pub-id></element-citation></ref><ref id="B149-pharmaceutics-14-02752"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>She</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Light-Triggered In Situ Gelation to Enable Robust Photodynamic-Immunotherapy by Repeated Stimulations</article-title><source>Adv. Mater.</source><year>2019</year><volume>31</volume><fpage>1900927</fpage><pub-id pub-id-type="doi">10.1002/adma.201900927</pub-id><pub-id pub-id-type="pmid">31012164</pub-id></element-citation></ref><ref id="B150-pharmaceutics-14-02752"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>ATP-Responsive Smart Hydrogel Releasing Immune Adjuvant Synchronized with Repeated Chemotherapy or Radiotherapy to Boost Antitumor Immunity</article-title><source>Adv. Mater.</source><year>2021</year><volume>33</volume><fpage>2007910</fpage><pub-id pub-id-type="doi">10.1002/adma.202007910</pub-id><pub-id pub-id-type="pmid">33788339</pub-id></element-citation></ref><ref id="B151-pharmaceutics-14-02752"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Engineering ROS-Responsive Bioscaffolds for Disrupting Myeloid Cell-Driven Immunosuppressive Niche to Enhance PD-L1 Blockade-Based Postablative Immunotherapy</article-title><source>Adv. Sci.</source><year>2022</year><volume>9</volume><fpage>2104619</fpage><pub-id pub-id-type="doi">10.1002/advs.202104619</pub-id><pub-id pub-id-type="pmid">35156339</pub-id><pub-id pub-id-type="pmcid">PMC9008797</pub-id></element-citation></ref><ref id="B152-pharmaceutics-14-02752"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Su</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Monroe</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Chakroun</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker&#8211;based immunotherapy</article-title><source>Sci. Adv.</source><year>2020</year><volume>6</volume><fpage>eaaz8985</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aaz8985</pub-id><pub-id pub-id-type="pmid">32490201</pub-id><pub-id pub-id-type="pmcid">PMC7239700</pub-id></element-citation></ref><ref id="B153-pharmaceutics-14-02752"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name></person-group><article-title>Injectable pH-responsive hydrogel for combinatorial chemoimmunotherapy tailored to the tumor microenvironment</article-title><source>J. Nanobiotechnology</source><year>2022</year><volume>20</volume><fpage>372</fpage><pub-id pub-id-type="doi">10.1186/s12951-022-01561-z</pub-id><pub-id pub-id-type="pmid">35953828</pub-id><pub-id pub-id-type="pmcid">PMC9367026</pub-id></element-citation></ref><ref id="B154-pharmaceutics-14-02752"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen-Mayfield</surname><given-names>T.-J.</given-names></name><name name-style="western"><surname>Sondel</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Q.</given-names></name></person-group><article-title>Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>1845</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-29388-0</pub-id><pub-id pub-id-type="pmid">35387972</pub-id><pub-id pub-id-type="pmcid">PMC8987059</pub-id></element-citation></ref><ref id="B155-pharmaceutics-14-02752"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Su</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel</article-title><source>Nat. Biomed. Eng.</source><year>2020</year><volume>4</volume><fpage>1090</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1038/s41551-020-0597-7</pub-id><pub-id pub-id-type="pmid">32778697</pub-id><pub-id pub-id-type="pmcid">PMC8848303</pub-id></element-citation></ref><ref id="B156-pharmaceutics-14-02752"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wrzesinski</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Stern</surname><given-names>E.</given-names></name><name name-style="western"><surname>Look</surname><given-names>M.</given-names></name><name name-style="western"><surname>Criscione</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ragheb</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jay</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Demento</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Agawu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Limon</surname><given-names>P.L.</given-names></name><etal/></person-group><article-title>Combination delivery of TGF-&#946; inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy</article-title><source>Nat. Mater.</source><year>2012</year><volume>11</volume><fpage>895</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1038/nmat3355</pub-id><pub-id pub-id-type="pmid">22797827</pub-id><pub-id pub-id-type="pmcid">PMC3601683</pub-id></element-citation></ref><ref id="B157-pharmaceutics-14-02752"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>X.-l.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>D.-h.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.-q.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Z.-y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.-d.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name></person-group><article-title>Injectable polypeptide-engineered hydrogel depot for amplifying the anti-tumor immune effect induced by chemo-photothermal therapy</article-title><source>J. Mater. Chem. B</source><year>2020</year><volume>8</volume><fpage>8623</fpage><lpage>8633</lpage><pub-id pub-id-type="doi">10.1039/D0TB01370F</pub-id><pub-id pub-id-type="pmid">32821893</pub-id></element-citation></ref><ref id="B158-pharmaceutics-14-02752"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>B.</given-names></name></person-group><article-title>In situ injection of dual-delivery PEG based MMP-2 sensitive hydrogels for enhanced tumor penetration and chemo-immune combination therapy</article-title><source>Nanoscale</source><year>2021</year><volume>13</volume><fpage>9577</fpage><lpage>9589</lpage><pub-id pub-id-type="doi">10.1039/D1NR01155C</pub-id><pub-id pub-id-type="pmid">33998643</pub-id></element-citation></ref><ref id="B159-pharmaceutics-14-02752"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name></person-group><article-title>Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy</article-title><source>Theranostics</source><year>2019</year><volume>9</volume><fpage>2299</fpage><lpage>2314</lpage><pub-id pub-id-type="doi">10.7150/thno.30577</pub-id><pub-id pub-id-type="pmid">31149045</pub-id><pub-id pub-id-type="pmcid">PMC6531311</pub-id></element-citation></ref><ref id="B160-pharmaceutics-14-02752"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><fpage>3049</fpage><lpage>3063</lpage><pub-id pub-id-type="doi">10.7150/thno.42385</pub-id><pub-id pub-id-type="pmid">32194854</pub-id><pub-id pub-id-type="pmcid">PMC7053188</pub-id></element-citation></ref><ref id="B161-pharmaceutics-14-02752"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>He</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>C.</given-names></name></person-group><article-title>A spontaneous multifunctional hydrogel vaccine amplifies the innate immune response to launch a powerful antitumor adaptive immune response</article-title><source>Theranostics</source><year>2021</year><volume>11</volume><fpage>6936</fpage><lpage>6949</lpage><pub-id pub-id-type="doi">10.7150/thno.58173</pub-id><pub-id pub-id-type="pmid">34093863</pub-id><pub-id pub-id-type="pmcid">PMC8171104</pub-id></element-citation></ref><ref id="B162-pharmaceutics-14-02752"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name></person-group><article-title>Promising alternatives of CD47 monoclonal antibody: An injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRP&#945; signal</article-title><source>Theranostics</source><year>2022</year><volume>12</volume><fpage>4581</fpage><lpage>4598</lpage><pub-id pub-id-type="doi">10.7150/thno.72310</pub-id><pub-id pub-id-type="pmid">35832081</pub-id><pub-id pub-id-type="pmcid">PMC9254232</pub-id></element-citation></ref><ref id="B163-pharmaceutics-14-02752"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name></person-group><article-title>Polarization of tumor-associated macrophages by TLR7/8 conjugated radiosensitive peptide hydrogel for overcoming tumor radioresistance</article-title><source>Bioact. Mater.</source><year>2022</year><volume>16</volume><fpage>359</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1016/j.bioactmat.2021.12.033</pub-id><pub-id pub-id-type="pmid">35386314</pub-id><pub-id pub-id-type="pmcid">PMC8965723</pub-id></element-citation></ref><ref id="B164-pharmaceutics-14-02752"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name></person-group><article-title>Injectable Supramolecular Hydrogel for Locoregional Immune Checkpoint Blockade and Enhanced Cancer Chemo-Immunotherapy</article-title><source>ACS Appl. Mater. Interfaces</source><year>2021</year><volume>13</volume><fpage>33874</fpage><lpage>33884</lpage><pub-id pub-id-type="doi">10.1021/acsami.1c08285</pub-id><pub-id pub-id-type="pmid">34275267</pub-id></element-citation></ref><ref id="B165-pharmaceutics-14-02752"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Vitamin C supramolecular hydrogel for enhanced cancer immunotherapy</article-title><source>Biomaterials</source><year>2022</year><volume>287</volume><fpage>121673</fpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2022.121673</pub-id><pub-id pub-id-type="pmid">35839587</pub-id></element-citation></ref><ref id="B166-pharmaceutics-14-02752"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Shim</surname><given-names>G.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>Y.-K.</given-names></name></person-group><article-title>Melanin-loaded CpG DNA hydrogel for modulation of tumor immune microenvironment</article-title><source>J.Control. Release</source><year>2021</year><volume>330</volume><fpage>540</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.12.040</pub-id><pub-id pub-id-type="pmid">33373649</pub-id></element-citation></ref><ref id="B167-pharmaceutics-14-02752"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kremenovic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bariswyl</surname><given-names>L.</given-names></name><name name-style="western"><surname>Robatel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Schenk</surname><given-names>M.</given-names></name></person-group><article-title>BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma</article-title><source>J. Immunother. Cancer</source><year>2022</year><volume>10</volume><fpage>e004133</fpage><pub-id pub-id-type="doi">10.1136/jitc-2021-004133</pub-id><pub-id pub-id-type="pmid">35732347</pub-id><pub-id pub-id-type="pmcid">PMC9226922</pub-id></element-citation></ref><ref id="B168-pharmaceutics-14-02752"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity</article-title><source>Oncoimmunology</source><year>2016</year><volume>5</volume><fpage>e1074374</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2015.1074374</pub-id><pub-id pub-id-type="pmid">27057439</pub-id><pub-id pub-id-type="pmcid">PMC4801446</pub-id></element-citation></ref><ref id="B169-pharmaceutics-14-02752"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Caserto</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>M.</given-names></name></person-group><article-title>An in situ hydrogel-mediated chemo-immunometabolic cancer therapy</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>3821</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-31579-8</pub-id><pub-id pub-id-type="pmid">35780226</pub-id><pub-id pub-id-type="pmcid">PMC9250515</pub-id></element-citation></ref><ref id="B170-pharmaceutics-14-02752"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>C.</given-names></name></person-group><article-title>A spontaneously formed and self-adjuvanted hydrogel vaccine triggers strong immune responses</article-title><source>Mater. Des.</source><year>2021</year><volume>197</volume><fpage>109232</fpage><pub-id pub-id-type="doi">10.1016/j.matdes.2020.109232</pub-id></element-citation></ref><ref id="B171-pharmaceutics-14-02752"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name></person-group><article-title>Injectable polypeptide hydrogel for dual-delivery of antigen and TLR3 agonist to modulate dendritic cells in vivo and enhance potent cytotoxic T-lymphocyte response against melanoma</article-title><source>Biomaterials</source><year>2018</year><volume>159</volume><fpage>119</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2018.01.004</pub-id><pub-id pub-id-type="pmid">29324304</pub-id></element-citation></ref><ref id="B172-pharmaceutics-14-02752"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name></person-group><article-title>Neoantigen Immunotherapeutic-Gel Combined with TIM-3 Blockade Effectively Restrains Orthotopic Hepatocellular Carcinoma Progression</article-title><source>Nano Lett.</source><year>2022</year><volume>22</volume><fpage>2048</fpage><lpage>2058</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.1c04977</pub-id><pub-id pub-id-type="pmid">35133159</pub-id></element-citation></ref><ref id="B173-pharmaceutics-14-02752"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>In Situ Transforming RNA Nanovaccines from Polyethylenimine Functionalized Graphene Oxide Hydrogel for Durable Cancer Immunotherapy</article-title><source>Nano Lett.</source><year>2021</year><volume>21</volume><fpage>2224</fpage><lpage>2231</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.0c05039</pub-id><pub-id pub-id-type="pmid">33594887</pub-id></element-citation></ref><ref id="B174-pharmaceutics-14-02752"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Francis</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Sestito</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Archer</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Manspeaker</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>O&#8217;Melia</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name></person-group><article-title>Thermosensitive hydrogel releasing nitric oxide donor and anti-CTLA-4 micelles for anti-tumor immunotherapy</article-title><source>Nat. Commun.</source><year>2022</year><volume>13</volume><fpage>1479</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-29121-x</pub-id><pub-id pub-id-type="pmid">35304456</pub-id><pub-id pub-id-type="pmcid">PMC8933465</pub-id></element-citation></ref><ref id="B175-pharmaceutics-14-02752"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Melia</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Manspeaker</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name></person-group><article-title>Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC</article-title><source>Cancer Immunol. Immunother.</source><year>2021</year><volume>70</volume><fpage>2179</fpage><pub-id pub-id-type="doi">10.1007/s00262-020-02792-5</pub-id><pub-id pub-id-type="pmid">33459842</pub-id><pub-id pub-id-type="pmcid">PMC8286278</pub-id></element-citation></ref><ref id="B176-pharmaceutics-14-02752"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engelhard</surname><given-names>V.H.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Mauldin</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Peske</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Slingluff</surname><given-names>C.L.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity</article-title><source>J. Immunol.</source><year>2018</year><volume>200</volume><fpage>432</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1701269</pub-id><pub-id pub-id-type="pmid">29311385</pub-id><pub-id pub-id-type="pmcid">PMC5777336</pub-id></element-citation></ref><ref id="B177-pharmaceutics-14-02752"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joshi</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Akama-Garren</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.-Y.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>A.</given-names></name><name name-style="western"><surname>DuPage</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tammela</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kerper</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Farago</surname><given-names>A.F.</given-names></name><etal/></person-group><article-title>Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses</article-title><source>Immunity</source><year>2015</year><volume>43</volume><fpage>579</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.08.006</pub-id><pub-id pub-id-type="pmid">26341400</pub-id><pub-id pub-id-type="pmcid">PMC4826619</pub-id></element-citation></ref><ref id="B178-pharmaceutics-14-02752"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohamed</surname><given-names>L.</given-names></name><name name-style="western"><surname>Elsaka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zamzam</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Elkady</surname><given-names>A.</given-names></name></person-group><article-title>Tumor Infiltrating Lymphocytes and Tertiary Lymphoid Structure as Prognostic and Predictive Factor for Neoadjuvant Chemotherapy in Stage II &amp; III Breast Cancer</article-title><source>Arch. Can. Res.</source><year>2018</year><volume>6</volume><fpage>17</fpage></element-citation></ref><ref id="B179-pharmaceutics-14-02752"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tseng</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Guley</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>Lipidecalcium phosphate nanoparticles for delivery to the lymphatic system and SPECT/CT imaging of lymph node metastases</article-title><source>Biomaterials</source><year>2014</year><volume>35</volume><fpage>4688</fpage><lpage>4698</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.02.030</pub-id><pub-id pub-id-type="pmid">24613050</pub-id><pub-id pub-id-type="pmcid">PMC4004378</pub-id></element-citation></ref><ref id="B180-pharmaceutics-14-02752"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Videira</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Botelho</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Gouveia</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Pedroso De Lima</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>A.J.</given-names></name></person-group><article-title>Lymphatic Uptake of Pulmonary Delivered Radiolabelled Solid Lipid Nanoparticles</article-title><source>J. Drug Target.</source><year>2002</year><volume>10</volume><fpage>607</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1080/1061186021000054933</pub-id><pub-id pub-id-type="pmid">12683665</pub-id></element-citation></ref><ref id="B181-pharmaceutics-14-02752"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohammad</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Amayreh</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Mazzara</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Reineke</surname><given-names>J.J.</given-names></name></person-group><article-title>Rapid Lymph Accumulation of Polystyrene Nanoparticles Following Pulmonary Administration</article-title><source>Pharm. Res.</source><year>2013</year><volume>30</volume><fpage>424</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1007/s11095-012-0884-4</pub-id><pub-id pub-id-type="pmid">22992832</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-14-02752-f001" orientation="portrait"><label>Figure 1</label><caption><p>Schematic illustration of the preparation and actions of NPs. (<bold>A</bold>) Microflowers were first synthesized via self-assembly of polymerized DNA and shRNA synthesized using the RCA of DNA templates to encode CpG and <italic toggle="yes">Stat3</italic> shRNA. (<bold>B</bold>,<bold>C</bold>) (<bold>B</bold>) Cationic polymers allowed the shrinking of microflowers to develop NPs capable of (<bold>C</bold>) lymphatic drainage for adaptive immune response. The figure is adapted from [<xref rid="B93-pharmaceutics-14-02752" ref-type="bibr">93</xref>] with permission from Springer Nature. Copyright 2017 Springer Nature.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-14-02752-g001.jpg"/></fig><fig position="float" id="pharmaceutics-14-02752-f002" orientation="portrait"><label>Figure 2</label><caption><p>Schematic illustration of the preparation and actions of SNA with liposomal nanodisc cores. (<bold>A</bold>) Antigens were conjugated to liposomal nanodisc via a disulfide bond and cholesterol-CpG were embedded on the phospholipid layers to afford an SNA structure where CpG was exposed to the nanodisc. (<bold>B</bold>) The nanodisc was drained into the LNs to instruct the antigen-specific CD8<sup>+</sup> T cells in LNs for anticancer immunotherapy. The figure is adapted from [<xref rid="B99-pharmaceutics-14-02752" ref-type="bibr">99</xref>] with permission from Springer Nature. Copyright 2017 Springer Nature.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-14-02752-g002.jpg"/></fig><fig position="float" id="pharmaceutics-14-02752-f003" orientation="portrait"><label>Figure 3</label><caption><p>Schematic illustration of the preparation and actions of pH-sensitive DNA nanodevice. (<bold>A</bold>) Rectangle-shaped DNA was prepared using staple strands and M13 bacteriophage DNA, which were further engineered to load tumor peptide-antigen-DNA conjugate antigens and double stranded RNA (dsRNA) adjuvants. pH-sensitive locking strands were then employed to generate tubular DNA nanostructures. (<bold>B</bold>) Mechanism of actions of the DNA nanostructures. pH-sensitive locking DNA was dehybridized to open the tubular structure, exposing the antigens and dsRNA outside to stimulate DC activation and presentation of antigens after draining into the LNs, followed by uptake by DCs, leading to antigen-specific CD8<sup>+</sup> T cell response for robust anticancer immunotherapy. The figure is adapted from [<xref rid="B104-pharmaceutics-14-02752" ref-type="bibr">104</xref>] with permission from Springer Nature. Copyright 2021 Springer Nature.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-14-02752-g003.jpg"/></fig><fig position="float" id="pharmaceutics-14-02752-f004" orientation="portrait"><label>Figure 4</label><caption><p>Schematic illustration of the preparation and lymphatic drainage of protein-fusion nanocages (PdNCs). (<bold>A</bold>) Self-assembled PdNCs (<bold>right</bold>) from a fusion protein (<bold>mid</bold>) containing hFTN and aPD-1 were prepared; these PdNCs were synthesized from a plasmid vector (<bold>left</bold>). (<bold>B</bold>) SDS-PAGE of the plasmid vector. (<bold>C</bold>) Representative TEM image of the PdNCs. (<bold>D</bold>) DLS size distribution of PdNCs (<bold>left</bold>) and control nanocages self-assembled from wild hFTN (<bold>right</bold>). (<bold>E</bold>) Quantification of the LN accumulation of PdNCs using ex vivo IVIS. * <italic toggle="yes">p</italic> &lt; 0.05 was analyzed by one-way ANOVA with Tukey&#8217;s post-hoc. Figures are reproduced from [<xref rid="B108-pharmaceutics-14-02752" ref-type="bibr">108</xref>] with permission from Elsevier. Copyright 2021 Elsevier.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-14-02752-g004.jpg"/></fig><fig position="float" id="pharmaceutics-14-02752-f005" orientation="portrait"><label>Figure 5</label><caption><p>Schematic illustration of the preparation and lymphatic drainage of DC-membrane cloaking NPs. (<bold>A</bold>) Preparation of aCD3 functionalized DC-membrane cloaking NPs by coating imiquimod-loaded PLGA NP with the DC membrane and conjugating aCD3 with the membrane. (<bold>B</bold>) The NPs drained into the LNs and elicited an antitumor immune response after s.c. administration. The figure is adapted from [<xref rid="B122-pharmaceutics-14-02752" ref-type="bibr">122</xref>] with permission from American Chemical Society. Copyright 2021 American Chemical Society.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-14-02752-g005.jpg"/></fig><fig position="float" id="pharmaceutics-14-02752-f006" orientation="portrait"><label>Figure 6</label><caption><p>Schematic illustration of the preparation, characterization, lymphatic drainage, and therapeutic effects of activated DC-derived exosomes. (<bold>A</bold>) Activated DC-derived exosomes were prepared using poly(I:C) and OVA and further decorated with aCTLA-4. (<bold>B</bold>) DLS size distribution of exosomes. (<bold>C</bold>) TEM images of exosomes. (<bold>D</bold>) Quantification of the LN accumulation of exosomes. (<bold>E</bold>) Tumor growth curves with exosomes. * <italic toggle="yes">p</italic> &lt; 0.05, ** <italic toggle="yes">p</italic> &lt; 0.01, and *** <italic toggle="yes">p</italic> &lt; 0.001 were analyzed by one-way ANOVA. Figures are reproduced from [<xref rid="B126-pharmaceutics-14-02752" ref-type="bibr">126</xref>] with permission from Elsevier. Copyright 2020 Elsevier.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-14-02752-g006.jpg"/></fig><fig position="float" id="pharmaceutics-14-02752-f007" orientation="portrait"><label>Figure 7</label><caption><p>Schematic illustration of the (<bold>A</bold>) preparation of multistage drug delivery systems and (<bold>B</bold>) distribution of cargos in dLNs. Figures are reproduced from [<xref rid="B128-pharmaceutics-14-02752" ref-type="bibr">128</xref>] with permission from Springer Nature. Copyright 2020 Springer Nature.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-14-02752-g007.jpg"/></fig><fig position="float" id="pharmaceutics-14-02752-f008" orientation="portrait"><label>Figure 8</label><caption><p>Lymphatic drainage and immune profiles of the tumor cell lysates (TCL) and poly(I:C)-loaded hydrogels. (<bold>A</bold>) Chemical structure of mPEG-poly(L-Valine). (<bold>B</bold>) Image of a hydrogel. (<bold>C</bold>) IVIS images of antigens-Cy7 administered and released from hydrogels. (<bold>D</bold>) Quantification of fluorescence signals at the injection site over time. (<bold>E</bold>) Quantification of the fluorescence signals of antigens-Cy7 at LNs. (<bold>F</bold>) Ex vivo IVIS images of the LNs at 96 h after injection. (<bold>G</bold>&#8211;<bold>I</bold>) Populations of (<bold>G</bold>) CD8<sup>+</sup> T, (<bold>H</bold>) CD80<sup>+</sup> DCs, and (<bold>I</bold>) MHCII<sup>+</sup> DCs in the dLNs. ** <italic toggle="yes">p</italic> &lt; 0.01, *** <italic toggle="yes">p</italic> &lt; 0.001, and **** <italic toggle="yes">p</italic> &lt; 0.0001 were analyzed by students&#8217; <italic toggle="yes">t</italic>-test. Figures are reproduced from [<xref rid="B171-pharmaceutics-14-02752" ref-type="bibr">171</xref>] with permission from Elsevier. Copyright 2018 Elsevier.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-14-02752-g008.jpg"/></fig><fig position="float" id="pharmaceutics-14-02752-f009" orientation="portrait"><label>Figure 9</label><caption><p>Characterization, lymphatic drainage, and anticancer immunotherapeutic effects of ICB mAbs-loading micelles in situ released from thermosensitive hydrogels. (<bold>A</bold>) Representative SEM image of F127-Gelatin thermosensitive hydrogels. (<bold>B</bold>) Cumulative release of aCTLA-4 mAbs from the hydrogel in response to MMP-9. (<bold>C</bold>) Representative image of the F127-Gelatin micelle in situ released from the hydrogel. (<bold>D</bold>) FRET assay to demonstrate the load of aCTLA-4 mAbs on the in situ micelle via confirmation of the FRET signal between FITC-labeled F127-Gelatin polymer and TRITC-labeled aCTLA-4. (<bold>E</bold>&#8211;<bold>H</bold>) Quantification of the fluorescence signals of AF647-labeled aCTLA-4 mAbs released from the hydrogel at LNs and tumor after i.t. injection into the primary tumor (1<sup>o</sup> tumor). (<bold>I</bold>) 1<sup>o</sup> and (<bold>J</bold>) 2<sup>o</sup> tumor growth curves with the hydrogel formulations. * <italic toggle="yes">p</italic> &lt; 0.1, ** <italic toggle="yes">p</italic> &lt; 0.05, *** <italic toggle="yes">p</italic> &lt; 0.01, **** <italic toggle="yes">p</italic> &lt; 0.001, and ***** <italic toggle="yes">p</italic> &lt; 0.0001 were analyzed by one-way ANOVA with Tukey post-hoc for E-H, two-way ANOVA with Tukey post-hoc for B, and ANOVA using linear mixed-effects model for I and J. Figures are reproduced from [<xref rid="B174-pharmaceutics-14-02752" ref-type="bibr">174</xref>] with permission from Springer Nature. Copyright 2022 Springer Nature.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-14-02752-g009.jpg"/></fig></floats-group></article></pmc-articleset>